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ABSTRACT 
 
 
 
CHARACTERIZATION OF THE C-TERMINAL DOMAIN OF  
THE P53 TUMOR SUPPRESSOR 
 
 
Bahar Shamloo 
Molecular Biology, Genetics, and Bioengineering, PhD Thesis, 2016  
Thesis supervisor: Batu Erman 
Keywords: p53, p53 CTM, CRISPR/Cas9 system, Human Colon Cancer 
 
 
 Half of all cancer cases have a mutated p53 gene.  The p53 protein’s C-terminal 
domain plays an important role in its post-translational modification.  We studied the 
function of this domain in endogenous p53 in HCT116 human colon cancer cell lines.  
We generated several C-terminal mutant (CTM) cell lines through CRISPR-Cas9 
mediated genome editing.  The focus of this study is three of these p53 CTM cell lines 
that encode 1) a truncated p53 protein (p53 Δ21 / Δ21); 2) a single amino acid deleted 
p53 protein (p53 ΔR379 / ΔR379); and 3) a p53 protein missing the C-terminus encoded 
by the last p53 exon (p53 Δ26 / Δ26).  We show that cells which express the p53 ΔR379 
protein (with deleted Arg379), grow slower than their wild type counterparts and cannot 
bind to DNA targets as efficiently as WT p53.  The p53 Δ21 mutant lacks 21 amino 
acids at the C-terminus.  This mutant p53 can accumulate after DNA damage and can 
bind to DNA targets efficiently; nevertheless, it shows a different transcription pattern 
for some genes that play important roles in ribosome biogenesis stress.  The p53 Δ26 
expressing mutant cell line lacks the last exon of p53 on both alleles, behaves in a very 
different way.  The phenotype of this mutant is similar to HCT116KO cells that do not 
express p53.  These mutant cells express truncated p53 and they grow much slower and 
go to senescence twice as fast as HCT116KO counterparts.  This p53 mutant cannot 
translocate into the nucleus after DNA damage induced by Doxorubicin treatment.  We 
assessed the expression of p53 target genes by quantitative RT PCR and found defects 
in the expression of these genes for all our CTM cell lines.  These results indicate that 
the p53 C-terminal domain is very critical for the protein’s function. 
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Özet 
 
 
 
P53 TÜMÖR BASKILAYICI PROTEİNİNİN C-TERMİNAL DOMAİN 
KARAKTERİZASYONU 
 
 
 
Bahar Shamloo 
Moleküler Biyoloji, Genetik ve Biyomühendislik, PhD Tezi, 2016  
Tez danışmanı: Batu Erman 
Anahtar kelimeler: p53, p53 CTM, CRISPR/Cas9 sistemi, İnsan Kolon Kanseri 
 
 
Tüm kanser vakalarının yarısında mutasyona uğramış p53 geni görülmektedir.  P53 
proteininin c-terminal domaini post-translasyon modifikasyonlarında önemli bir rol 
sahibi.  Bu çalışmada, HCT116 insan kolon kanser hücre hatlarında bulunan endojen 
p53’te bu domainin fonksiyonu çalışılmıştır.  CRISPR-Cas9 aracılı genom düzenleme 
tekniği ile C-terminal mutant (CTM) hücre hatları oluşturulmuştur.  Bu çalışmada 
oluşturulan p53 CTM hücre hatlarından; 1) kesilmiş p53 proteini (p53 Δ21 / Δ21), 2) 
tek amino asidi silinmiş p53 proteini (p53 ΔR379 / ΔR379), 3) son p53 eksonu 
tarafından kodlanan C-terminali içermeyen p53 proteini; içerenler üzerinde 
durulmuştur.  Elde edilen veriler ışığında, p53 ΔR379 proteinini (silinmiş Arg379 ile) 
ifade eden hücrelerin doğal fenotipe (WT p53) göre daha yavaş büyüdükleri ve DNA 
hedeflerine WT p53 kadar verimli bağlanmadıkları belirlenmiştir.  The p53 Δ21 
mutantının C-terminalinde 21 amino asidi bulunmamaktadır.  Bu mutant p53 DNA 
hasarı sonrası birikebilmekte ve DNA hedeflerine verimli bir şekilde 
bağlanabilmektedir, buna rağmen bu hücreler ribozom biyogenez stresinde önemli rol 
oynayan genler özelinde daha farklı bir transkripsiyon şablonuna sahiptir.  p53 Δ26 
biyosentezleyen mutant hücre hattı ise her iki alelde p53’ün son eksonunu 
içermemektedir ve çok farklı bir davranış sergilemektedir.  Bu mutantın fenotipi p53’ü 
ifade etmeyen HCT116KO hücreleri ile benzerdir.  Bu mutant hücreler kesik p53 
proteini ifade ederler ve çok daha yavaş büyümektedirler ve HCT116KO mukabillerine 
göre iki kat hızlı hücre yaşlanmasına (senesans) girerler.  Bu p53 mutantı Doxorubicin 
tedavisi ile indüklenen DNA hasarı sonrasında hücre çekirdeğine doğru yer 
değiştirememektedir.  Bütün CTM hücre hatlarında, p53 hedef genlerinin ifade 
seviyeleri kantitatif RT PCR ile incelenmiş ve bu genlerde kusurlar tespit edilmiştir.  Bu 
sonuçlar, p53 C-terminal domaininin proteinin fonksiyonu için çok hassas olduğunu 
göstermektedir. 
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1.  INTRODUCTION 
	  
	  
	  
1.1. The p53 Protein 
 
 
1.1.1. p53; Guardian of the Genome 
 
The p53 protein is mutated in more than 50% of human cancer cases.  The 
prevalence of the p53 mutation depends on the cancer type, ranging from 80-90% in 
ovarian or lung cancer to as low as 5% in cervical cancer1.  Whether by mutation in the 
TP53 gene or by the perturbation of p53 associated pathways, p53 is inactivated in 
almost every tumor2.  Li and Fraumeni first discovered germline mutations in the Tp53 
gene in 1969 and defined these mutations as familial cancer syndrome3,4.  Although p53 
is the most studied protein during the last 40 years in over 80,000 articles, there is still 
much to discover about the complexities of this protein.   
p53-mediated cellular responses: p53 is involved in many cellular responses 
such as cell cycle arrest, induction of senescence, DNA repair, and apoptosis by 
controlling transcription of its target genes5.  Upon cellular stress signals such as 
hypoxia, oncogenic stress, oncogene activation, DNA damage, telomere erosion, or 
ribosomal stress, p53 protein becomes stabilized.  This stabilization is mediated by 
multiple post-translational modifications such as methylation, phosphorylation and 
acetylation.  p53 stabilization results in its translocation into the nucleus and the 
induction of transcription of p53 target genes.  Transcriptional regulation of p53 target 
genes leads to cellular responses such as cell cycle arrest or apoptosis, depending on the 
severity and irreparability of the damage6.  One of the p53 protein’s transcriptional 
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targets is the mdm2 gene that encodes the MDM2 protein.  MDM2 keeps cellular p53 
protein levels under strict control along with its homolog, MDMX, by forming a 
heterodimer and acting as an E3 ubiquitin ligase7.  MDMX acts as a p53 negative 
regulator in two ways; first by preventing MDM2 from auto-ubiquitination, and second 
by binding to the transactivation domain of p53 and inhibiting its activation8,9  (Figure 
1.1).   
 
 
 
	  
Figure	  1	  
Figure 1.1: p53/MDM2/MDMX regulatory loop. The MDM2/p53 autoregulatory 
feedback loop is shown at the top left.  Mono-ubiquitination of p53 by MDM2 binding 
to its N-terminal leads to p53 nuclear export (top right).  The activation of 
MDM2/MDMX and other E3 ligases or E4 factors in the cytoplasm leads to the poly-
ubiquitination and 26S proteasomal degradation of p53 (bottom right).  Following DNA 
damage stress, p53 N-terminal gets phosphorylated and MDMX is poly-ubiquitinated in 
the MDM2/MDMX complex (bottom left).  This results in MDMX degradation, loss of 
the activator component of MDM2/MDMX E3 complex, p53 stabilization and 
accumulation10. 
 
 
M
DM
2$
ge
ne
$
tr
an
sc
rip
,o
n$
Nucl
eus$
Cyto
plasm
$
PolyUb7p53$
MDMX$degrada,on$
DNA$damage$response$
p53$degrada,on$
Default$p53$degrada,on$
DNA$damage$
$signaling$
p53$
p53$
p53$
p53$
p53$
MDM2$
MDM2$ MDM2$
MDM2$ MDM2$
p53$
p53$
26S$proteasome$
MDM2$
p53$
MDMX$
MDMX$
p53$
MDM2$
MDM2$
MDMX$
26S$proteasome$
p53$
O
th
er
$E
3/
E4
$li
ga
se
$
ph#
U#
U#
U#
U#
U# U#
U#
U#
U#U#
U#
U#
U#
U#
U#
U#U#
U#
U# U#
U#
U# U#
U#
U#
U#
U#
	   3	  
 
p53 and ribosome biogenesis stress: Ribosomal stress affects the p53/MDM2 
interaction11.  The nucleolus is a sub-nuclear compartment in which ribosome 
biogenesis occurs.  rRNA genes in tandem repeats are translocated to the nucleolus and 
are transcribed by RNA polymerase I (Pol I) in a strictly regulated manner.  Because 
ribosome biogenesis is an extremely energy-consuming process for cells that requires 
high fidelity, it is suppressed under cellular stress11.  The misregulation of ribosome 
biogenesis is detected in various human cancer cases12.  The rRNA together with 
ribosomal proteins (RPs) are assembled in the nucleolus hub to construct the 40S and 
60S ribososmal subunits13.  40S subunit has 18S RNA and 33 proteins; 80S subunit has 
5S, 28S, and 5.8S RNA subunits and 46 proteins14.  The nucleolus and the ribosome 
biogenesis apparatus play an important role in sensing cellular stress.  Upon severe 
cellular stress, such as Doxorubicin treatment, the nucleolus is condensed and nucleolar 
proteins and RNAs are packed in structures called nucleolar caps15.  This alteration in 
nucleolar morphology is an important factor in p53 activation upon stress16.  Inhibition 
of rRNA processing and transient knock down of the activator subunit of PolI is 
followed by p53-dependent cell cycle arrest17,18.  Ribosomal proteins, such as RPL11, 
similar to the ARF tumor suppressor, bind to MDM2 and inhibit its interaction with p53 
by generating a stable complex with MDM219.  Two main models are suggested for the 
RP/MDM2/p53 interaction: a) upon ribosomal stress, RPs are diffused into the nucleus 
and bind to MDM2, inhibiting its nuclear export into the cytoplasm, b) following the 
40s depletion, translation of RPL11 is enhanced from its mRNA, it accumulates and 
induces p53 activity; the RPL11-MDM2 complex binds to the RP11 promoter and 
induces its transcription as well20.  RPL11 and RPL5 are transferred from nucleolus into 
the nucleus, bind to MDM2 and activate p5321.  Other RPs cannot enter the nucleus and 
are quickly degraded12,21.  It should be noted that PRs, not only increase p53 activity in 
an MDM2-dependent manner, but they could also bind to the promoter of a number of 
the p53 regulatory genes.  As an example, RPL11 is important in the recruitment of 
p300/CBP (a p53 transcriptional co-activator), which leads to p53 K382 acetylation and 
p53 activation20.   
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1.1.2. p53 Structure 
  
The human p53 protein consists of 393 amino acids and forms a homo-tetramer 
when active.  p53 protein is composed of 5 domains:  the transactivation domain (TAD; 
divided into TAD1 and TAD2), the proline rich region (PRR), the DNA binding domain 
(DBD), the tetramerization domain, and the C-terminal regulatory domain22.  In 
addition to these structurally well defined domains, the p53 protein has intrinsic 
disordered regions to provide its conformational adaptability23.  Post-translational 
modification (PTM) occurs under various conditions to regulate p53 stability, activity, 
and protein-protein interactions (Figure. 2)24.   
Transactivation Domain: The N-terminal transactivation domain of p53 is 
divided into two sub-domains: TAD1 (amino acid 1-40) and TAD2 (amino acid 41-61).  
TAD is important in activation of the p53 protein by interacting with the p300, CREB 
binding proteins (CBP), and MDM2/MDMX proteins25.  Phosphorylation of this 
domain is important because it specifies the group of proteins that can interact with the 
p53 protein and turn its function on and off26.  p300/CBP and MDM2 compete over 
their binding site on the p53 N-terminal domain and depending on the post-translational 
modification of this domain, the affinity of MDM2 or p300/CBP changes27,28.  
Hydrophobic amino acids in TAD1 (such as L22 and W23) are important in MDM2 
binding 29.  MDM2 binding to the TAD results in the ubiquitination of the CTD of p53.  
The interaction of MDM2 with the TAD must required the CTD as CTD mutant p53 
proteins cannot interact with MDM2 30.  Under DNA damage stress, post-translational 
modification of TAD1 (e.g. T18 phosphorylation) and CTD (e.g. K382 acetylation) 
results in the decrease of the affinity of MDM2 to its N-terminal p53 binding site 
decreases and the affinity of p300-CBP for p53 increases.  These modifications 
transcriptionally activate the p53 protein 31,32.  Some modifications (such as S15 
phosphorylation) can directly increase p53 affinity for p300/CBP as well33.  
DNA binding Domain: The p53 protein binds to DNA response elements with 
two half-site motifs with variable spacer lengths (0-13 base pair).  Each of these motifs 
has a general sequence of RRRCWWGYYY (R = A or G; W= A or T; Y = C or T)34,35.  
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In a tetramerized p53, all four DBD bind to these binding sites cooperatively36.  Thus 
the p53 tetramer binds to the sequence RRRCWWGYYYN(0-13)RRRCWWGYYY, 
where each half site is bound by a dimer.  The DBD consists of two anti-parallel β 
sheets that make a β–sandwich.  These two sheets join using several elements such as β 
hairpins, α–helix “H1”, and α–helix “H2”.  The latter interacts with C-terminal end of 
the DBD.  α–helix “H1” and loop L3 have Zn-chelating residues that coordinate a zinc 
atom (zinc finger motif) 37,38.  L120 (in contact with second R of the p53 response 
element) and R273 that contacts with DNA phosphate backbone are examples of amino 
acids that are important in DNA binding.  Mutations in these amino acids are frequently 
reported in tumor genomes as carcinogenic mutations.  Mostly, mutations in cancer 
cases reside in the DBD and these mutations either disturb p53 DNA binding (class I 
mutations) or change the p53 conformation (class II mutations)39.  Class I mutations 
refer to surface residues and do not change p53 conformation as much as class II.  DBD 
mutations are generally associated with cancer onset due to three reasons: a) they affect 
transcription activation by p53, because DNA binding efficiency changes40, b) 
mutations affect the folding of p53 protein at body temperature41, and c) Arginine 
residues are abundant in the DBD and these amino acids are susceptible to mutation 
because their codons are affected by CG dinucleotide error-prone repair 42.  In addition 
to DNA, the DBD also interacts with p53-binding proteins, which change the protein’s 
conformation.  For example, 53BP1 and 53BP2 (ASPP2) proteins bind to the DBD.  
These interactions are important for the function of p53 as 53BP1 activates ataxia-
telangiectasia mutated (ATM) in response to DNA damage43,44.  ATM and ATR are two 
proteins that are important for the pathway that results in the phosphorylation of the N-
terminal TAD of p53 that results in its dissociation from MDM2. 
Tetramerization Domain: The tetramerization domain of p53 starts from 
amino acid 324 to 355; β–strand (326-333) and α–helix (335-354) in each of four 
monomers form a V-like shape.  G334 is very important in the secondary structure and 
its mutation leads to cancer 45.  M330 and L344 reside in the center of the tetramer are 
responsible for the stoichiometry of the structure46.  In cancer studies, mutation rate in 
the tetramerization domain is many folds (~100 folds) less than the mutation rate in 
DBD47; one reason is the high melting temperature (70◦C) of the oligomerization 
domain that inhibits unfolding of the domain in body temperature following 
mutations48, and the second reason is that generally dominant negative activity of the 
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mutant protein does not happen for this domain49.  The side chain size of the 
hydrophobic residues is extremely critical for the folding of this domain and 
oligomerization stoichiometry as the V-shape folding changes to L-shape following 
specific mutations (such as for F341 and L344)50,51.  Tetramerization of p53 leads to 
masking of the Leucine rich nuclear export signal that resides in the tetramerization 
domain and determines cellular p53 localization.  This structural change is also a 
hallmark for stressed cells since in normal cells, all monomer, dimer, and tetramer states 
of p53 are present in different ratios; on the other hand, cells under stress stabilize 
amount of tetramer p53 even before p53 level increase52.  Generally various 
modifications on p53 can favor a protein-protein interaction, or vice versa. 
Proline-Rich Region: Proline-rich regions reside in the N-terminus (amino acid 
71-93; ten Proline residues) and C-terminus (294-323; seven Proline residues).  Proline 
amino acids are important for an efficient folding of the p53 protein53 and its interaction 
with SH3 domain containing proteins (such as 53BP2)54.  Poly-proline regions have 
been shown to be critical for the activity of p53, specially its role in inducing 
apoptosis55.   
C-Terminal Domain: C-terminal basic domain starts from amino acid 356 until 
the last amino acid of the p53 protein (393).  This domain is flexible and is exposed to 
many post-translational modification56,57,58.  p53 CTD post-translational modification 
plays an important role in p53 conformational change, DNA-binding specificity, 
oligomerization state, and nuclear import/export59.  p53 CTD has been solved in 
complex with Sir2 (a protein deacetylase) and S100B (Calcium binding p53 inhibitor); 
both change p53 conformation completely differently60,61.  Sir2 family has roles in 
DNA repair, genome stability and transcriptional silencing62.  For example, miR-
34a/sirtuin 1(SIRT1)/p53 is a p53 regulatory pathway in which p53 is suppressed by 
SIRT1 deacetylase activity under normal unstressed conditions.  miR-34a modulates 
expression of numerous genes, including SIRT1.  p53 increases transcription of this 
microRNA; this up-regulation in turn leads to suppression of SIRT1 and increasing p53-
dependent apoptosis63.  Another member of this complicated circuit is the c-Jun protein 
and its activator, JNK (c-Jun activator kinase), which are responsible for re-directing 
p53 cell cycle arrest activity to robust apoptosis.  JNK also plays a role in cell 
proliferation and cell cycle progression64.  The positive feedback loop between p53 and 
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JNK is not completely known, but the p53 protein induces pro-oxidant genes, which 
increase reactive oxygen species (ROS), promoting JNK activation65. 
 
 
 
 
	  
Figure	  2	  
Figure 1.2: Post-translational modification (PTM) of the p53 protein.  At the top, p53 
domains are shown as: TAD (Transactivation domain), TET (Tetramerization domain), 
REG (C-terminal regulatory domain).  Upon stress, several PTMs accumulate and 
activate p53.  Different PTM patterns regulate p53 protein-protein interactions, 
transactivation activity and stability.   
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1.1.3. p53 Evolution 
 
 The history of the p53 protein goes back to the appearance of early metazoan 
sponges, cnidarians, placozoan and even protists, about 1-2 billion years ego.  This 
history shows the importance of p53 in cancer development ever since66,67.  Even in 
unicellular close relatives of metazoans (M.  brevicollis) some metazoan-specific p53 
transcription factor family member proteins are detected.  This finding shows the role of 
p53 family proteins in the evolution of multicellular organisms by playing a role in the 
maintenance of genome integrity under stress conditions68,69.  p53, p63, and p73 are 
three family members found in vertebrates that evolved from a primordial common 
ancestor gene.  The proteins encoded by these three genes have distinct responsibilities; 
p63 and p73 participate in developmental and differentiation, while p53 functions as a 
tumor suppressive protein70.  These three paralogs are present in the cartilaginous fishes 
and the jawless lamprey, showing the evolutionary path of the p53 family71.  p63 and 
p73 have evolved slower compared to p53 in vertebrates 72.  Structurally, the DNA 
binding domain in p53 is more stable compared to those of p63 and p73; p53 has 
evolved slightly according to the organismal temperature and thermodynamics of the 
protein71,73.  p63 and p73 need their second helix in their tetramerization domain which 
is lost during the evolution of the p53 protein; this region can be traced in many fish 
p53 sequences such as in zebrafish.  In human, p53 C-terminal undiscriminating binding 
site and also the flexible linker in between tetramerization and C-terminal regulatory 
domains compensate lack of this second helix74,75.  Shortening of tetramerization 
domain is most probably directly related to the p53 protein’s novel functions in genome 
stability, while C-terminal domain maintains its length and features during vertebrate 
evolution of the protein to a great extent75.  As a consequence, tetramerization and DNA 
binding domain have changed in p53 to obtain additional adaptive functions, while 
keeping their key role in cell integrity maintenance.  MDM2 family protein is highly 
conserved in primitive metazoans, but MDM2 gene is lost in some organism, for 
example in C. elegans and Drosophila, which are rapidly evolving organisms 75,76.  
Homologs of p53- and MDM2-family in primitive protozoans (T. adhaerens) interact 
through the N-terminal domain of MDM2-like protein and TAD of putative p53 family 
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protein77,78.  p53-MDM2 regulation has grown more complicated during divergence of 
MDM2 and MDMX from an ancestral MDM2-like gene79.   
MDM2 consists of four evolutionary conserved regions: N-terminal domain, 
acidic region, zinc-finger, and RING domain, among which RING domain is the most 
conserved.  This domain is responsible for homo- and hetero-dimerization of MDM2 
family members and also mediates E3 ubiquitin ligase activity of MDM2, established 
nearly 500 million years ago in vertebrates80.  As mentioned before, MDMX doesn’t 
have intrinsic E3 ubiquitin ligase activity8.  Other than MDM2 family as the master 
regulator of p53, there are other E3 ubiquitin ligase proteins, such as TRIM24, 
TOPORS, and CARPs that evolved independently and are probably more important in 
N-terminally truncated p53 isomers81,82.  There still remains much to be discovered 
about these non-MDM2, E3 ubiquitin ligases; if they are expressed in a tissue specific 
manner in an indicated developmental stage or if signal transduction pathways control 
them.  Answering these questions could lead to new therapeutic strategies for cancer 
treatment in the future. 
 
 
1.1.4. p53 Mutations and Cancer and Therapeutic Approaches 
 
 Mutations that affect transcriptional activity of the p53 protein: Up to now, 
many mutations in different domains of the Tp53 gene have been reported.  Tp53 is 
polymorphic in coding and non-coding regions.  Mutant p53 protein are able to change 
the microenvironment of the solid tumor in several ways such as modulation of 
extracellular matrix components, changing the secretion pattern of interleukins, 
cytokines, enzymes, and generally the secretome of the tumor cells, and last but not 
least, affecting the crosstalk between stromal and tumor cells83.  For instance, mutant 
p53 binds to the promoter of the secretory interleukin-1 receptor antagonist (sIL-1Ra) 
gene, suppressing its production and generating a chronic pro-inflammatory 
microenvironment, whereas wild type p53 is unable to interact with this interleukin 
gene under normal conditions84.  Also, prostate-specific antigen (PSA) mRNA levels is 
directly correlated with mutant p53 mRNA, associated with more aggressive cancer 
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while wild type p53 strongly suppresses PSA gene transcription85.  Mutant p53 can also 
trigger neo-vascularization by increasing the activity of transcription factors (e.g. E2F1) 
of pro-angiogenic cytokine stabilizers (IL8 and GRO-α)86.  Importantly, the Warburg 
effect is stimulated by mutant p5387; cancer cells with mutant p53 induce glycolysis by 
targeting genes that are responsible for energy metabolism (such as Parkin) and 
promote glucose transporter 1 (GLUT1) translocation to the plasma membrane, 
increased glucose uptake and lactate production88,89.  Most of these pro-cancer 
mutations reside in the DNA binding domain of the p53 protein, inhibiting its binding to 
target gene control elements upon stress.  Some of these somatic mutations are R175H, 
Y220C, G245S, R248Q/W, R249S, R273C/H, and R282W.  The most frequent germ-
line mutation in tetramerization domain is R337H1,90.  Yet another class of pro-cancer 
p53 mutations do not alter the transcription activity of the p53 protein, but lead to 
defects in mRNA stabilization and control by micro RNAs 91,92.  Surprisingly, very few 
p63 or p73 mutations are reported in relation with cancer cases.   
Even a single amino acid change in the Tp53 gene can cause developmental or 
metabolic changes.  As an example, the P72R mutation causes metabolism defects.  R 
allele variants are found mostly in cold climates and are related to obesity and metabolic 
dysfunction93.  High cancer prevalence in African and African-American individuals 
with the P47S polymorphism was recently identified.  This study identified that even 
heterozygote carriers of the S47 mutation develop carcinoma (HCC).  A possible 
explanation for this phenotype is that HCC patients might have lost their wild type p53 
allele at some point during disease development94.  The interesting fact about Tp53 gene 
mutations is that the effect of the mutation on the p53 protein function is allele 
dependent, meaning that depending on which allele is mutant, a dominant-negative 
phenotype or a gain of function is possible; invasion or metastasis phenotypes in the 
tumors are an example of this phenomenon95.   
Mutations that affect the stability of the p53 protein: Some p53 mutations 
affect the structural stability of the protein by disturbing its kinetics, while other 
mutations inhibit DNA-p53 interactions96,97.  Mutation in any one of R248, R273, or 
R280 perturbs transcription activity of p5398.  The DNA binding domain of the p53 
protein has a rather low melting point at 44-45◦C (temperature-sensitivity phenotype).  
This intrinsic property results in the destabilization and unfolding of mutant p53 
proteins (e.g.V143A, Y220C, and F270L) at body temperature98,99,100.  Small-molecule 
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stabilizers could be introduced to regain the functionality of these mutant proteins.  
There are other structural mutations that change wild type folding of the p53 protein, 
regardless of the melting point such as R249S that effect p53 hairpin conformation, 
caused by aflatoxin B1101.  Zinc binding is extremely important for p53- DNA minor 
groove interactions, therefore if any mutation occurs in this region of DBD (C176F, 
H179R, C238Y, and C242S) it would be deleterious to DNA binding97.  R175 is also a 
hotspot for DBD mutations; it resides close to Zinc binding region; if a histidine 
substitutes for arginine, not only is the melting point of the mutant p53 drastically 
decreased, but also its affinity for zinc-binding is reduced98.  Nevertheless, if an amino 
acid with a smaller side chain (e.g. alanine) replaces arginine, the mutation would be 
less damaging97.  Aside from the changes mentioned above, some mutations in DBD 
lead to aggregation of p53 as an amorphous and fibrillar nucleation due to unfolding 
and again irreversible aggregation of DBD in dominant negative unstable mutants97,102.  
For instance, unfolding of the p53 protein leads to Ile254 exposure that causes 
aggregation of p63 and p73 and formation of co-aggregates in mutant cells103.  
Tetramerization domain mutations are not as frequent as DBD mutations.  R337H is the 
most common mutation in this domain that disturbs the salt bridge between R337 and 
Asp352 leading to the destabilization of p53 tetramers in a pH dependent manner104.  
R175H and R273H Tp53 missense mutations are also responsible for aggressive and 
metastatic cancer in which mutant p53 accumulates in cancer cells105,106. 
 
Mutations that affect the stability of the p53 mRNA and protein: Eight 
percent of somatic p53 mutations lead to premature stop codons that result in the rapid 
degradation of the mRNA encoded by the TP53 gene in a process called nonsense 
mediated mRNA decay (NMD)107.  Nonsense mutations, such as R196X or R213X 
cause more than 500,000 new cancer cases every year1,90.  Aminoglycins and antibiotics 
(e.g. gentamicin), despite their toxicity, are used as therapeutic strategies to suppress 
NMD by binding to the ribosomal decoding center107,108.   
Mutations in p53 protein regulators: In many cancer cases the p53 protein is 
wild type but MDM2 and MDMX are over-expressed which leads to excess p53 
degradation 7.  Small molecules such as RITA that binds to the N-terminal domain of 
p53, or Nutlin that binds to the N-terminal domain of MDM2 abolish the p53-MDM2 
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interaction, are used as cancer drugs for such cases109,110.  The p53 binding pocket of 
MDM2 and MDMX are structurally different.  Activating p53 at its utmost level in 
therapeutic approaches requires dissociation from both MDM2 and MDMX7.  MDMX 
has an auto-inhibitory motif in which the amino acids W200 and W201 fold back and 
mimic the MDMX-p53 TAD.  This motif reduces the inhibitory effect of MDMX up to 
100 fold compared to MDM2.  Under normal conditions, casein kinase Iα binds to these 
amino acids to prevent auto-inhibition111,112; blocking this interaction triggers auto-
inhibition of MDMX and therefore could be an effective application in therapy.  
Stabilization of MDM2 also causes p53 degradation.  Some MDM2 stabilizers such as 
wild-type p53-induced phosphatase-1 (Wip1) are over-expressed in tumor cells.  This 
molecule is also a target for small-molecule inhibitors for cancer therapy113,114. 
Mutation in the p53 protein that affects metabolism: Glycolysis is an 
important pathway that plays a role in carcinogenesis.  p53 is an inhibitor of the gene 
encoding Tp53-induced glycolysis and apoptosis regulator (TIGAR)88.  Colon cancer 
cells with mutant p53 were shown to benefit from the over expression of TIGAR which 
increased the antioxidant response, supporting cancer progression115.  In the absence of 
wild type p53, the insulin-receptor gene is also overexpressed.  Increased insulin 
signaling interferes with the glycolysis pathway and promotes tumor growth116.  The 
role of p53 in metabolism is very important but this connection has been underestimated 
in many cancer studies117.  Mostly, cell cycle arrest and apoptosis has been the main 
focus for cancer cells with mutant p53.  A recent study with a with p533KR/3KR, a mouse 
model where three Lysine residues in the p53 C-terminal were mutated, showed that 
senescence, apoptosis, and cell cycle arrest were defective as expected.  Unexpectedly 
the same study found that glycolysis was inhibited while the generation of reactive 
oxygen species (ROS) was maintained.  This mutant p53 was responsible for sending 
cells to ferroptotic cell death in response to stress 118.  Although mutant p53 can have a 
dominant negative effect on wild type p53 in p53 heterozygous mutants, at some point 
mutant p53 can retain their metabolic activities due to the dissociation between 
metabolic and cell cycle arrest activities of the p53 protein, such as what happens in Li-
Fraumeni syndrome119,120.   
The p53 protein’s metabolic responsibilities are partly mitochondria related.  
p53 is known to translocate to the mitochondria and regulate the expression of 
mitochondrial genes.  p53 is also important for mitochondrial genome (mtDNA) 
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homeostasis121,122.  The metastatic potential of cancer cells with mutated Tp53 was 
recently found to be correlated with to their increased mitochondrial respiration and 
antioxidant capacity123.   
Mutations in the C-terminal domain of the p53 protein: The C-terminal 
domain (CTD) of p53 where many post-translational modifications occur, is also target 
of many cancerous mutations.  For example, K382 deacetylation is induced by NAD+-
dependent sirtuin deacetylases (SIRT1) and SIRT2; this deacetylation has an inhibitory 
effect on p53.  SIRT1/SIRT2 overexpression is the main reason for chronic 
myelogenous leukemia and inhibition of these proteins is an effective anticancer 
therapy124.  Lysine residues in the CTD take part in DNA binding and transcriptional 
activation by p53.  These residues act as an anchor for the DNA phosphate backbone 
while p53 binds to its target genes125,126.  Another study found that the CTD was 
necessary for tetramer formation using an induced-fit mechanism127.  The CTD results 
in the stabilization of the DNA-p53 complex by changing the conformation of the DBD.  
Laptenko et. al. compared the DNA binding capability of three CTD mutants by ChIP-
Seq128.  While p53 with wild type CTD binds to 335 target genes, the p536KR mutant 
binds to 278 targets; even less binding is reported for the mutant p536KQ and the Δ30 
mutant (175 sites)128.  Therefore, the CTD is a positive regulator of DNA binding by the 
p53 protein129.  These recent findings contradict earlier experiments that identified the 
p53 CTD as an inhibitor of DNA binding130.  CTD mutations may change the stability 
of p53-DNA complex in a target dependent manner.  If we divide p53-binding sites into 
three subgroups, they could be: a) high affinity distal binding sites (such as the site in 
the p21 gene), b) medium affinity distal binding sites (such as the site in the PUMA 
gene), and c) closely-spaced low affinity binding sites (such as those in the MDM2 
gene).  Truncated p53 CTM mutation (p53Δ30) and p536KQ completely lose their affinity 
to the third group, unlike wild type p53 and p536KR 128,131.  It is known that the DBD of 
p53 changes the conformation of its loop L1 from inward to outward to sit in the major 
groove of its DNA target.  When a p53 tetramer interacts with a target sequence,, three 
parts of the p53 protein is involved in the binding; Zn-coordinated H1 helix with its 
H178 interact with the N-terminus; H179 in the helix communicate with p53 regulatory 
CTD (last 30 amino acids); β-sandwich and the DBD cooperation132.  These three 
mentioned interactions are all crucial for transcriptional activity of the p53 protein.  The 
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link between the CTD and the DBD could potentially result in the functional regulation 
of p53 DNA binding by the CTD 133.   
The p53 C-terminal domain also has an important effect on its nuclear 
translocation 128.  A nuclear localization signal was found both in the N-terminal and C-
terminal regions of the p53 protein134,135.  As mentioned before, MDM2 ubiquitination 
leads to the destabilization of p53 protein, but this post-translational modification by 
MDM2 is also important for the nuclear localization of the p53 protein to the extent that 
in the absence of the six lysine residues in CTD, nuclear export of p53 is 
perturbed136,137.  Our study, which created new mutant cell lines that express various 
CTD mutants of p53 addresses the importance of this domain in p53 functions outlined 
here. 
 
 
 
 
 
1.2.  Genome Editing Tools 
 
 
 
1.2.1. A Brief History of Genome Engineering 
 
“Genome engineering can be defined as directed modification of the gene 
complement of a living organism”, as John F. Morrow described in his article in 1976. 
Treatment of inherited diseases and genetic transformation of plants are the most crucial 
beneficial uses of genetic engineering138. The aim of genome engineering is to target a 
specific region to introduce a desired mutation without off-targeting any other sequence 
in the genome. After years of unsuccessful attempts at genome engineering, recently 
genome editing proteins such as Zinc Finger Nuclease (ZFN), Transcription Activator-
Like Effector Nuclease (TALEN), and Clustered Regularly Interspaced Short 
Palindromic Repeats (CRISPR) were discovered. 
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Introducing viral DNA in mammalian cells (infection) in 1968 by J. Sambrook 
et al., was the preliminary efforts in gene delivery 139. However, infection was efficient 
but not site-specific. Genetic manipulation of genomes with rare-cutting homing 
endonucleases, with recognition sites much longer than bacterial restriction enzymes, 
were used to introduce a limited number of double strand breaks (DSB) in the 
genome140. However, this method was not applicable for many regions on the genome. 
An ideal genome engineering system needs to target a specific genomic region. In 2004 
Akiko Nomura and Yukio Sugiura succeeded in creating mutant Zinc finger proteins, 
which could function as a novel artificial nuclease that targeted desired genomic 
sequences. They showed selective hydrolysis of DNA duplexes by three tandem zinc 
finger mutants141. ZFN was a great step forward in site-specific genome engineering, 
but target selectivity was limiting and their construction was expensive and technically 
challenging142.  
 
 
1.2.2. TALEN Proteins 
 
In 2011, transcription activator-like (TAL) effectors, started a new trend in user-
friendly genome engineering tools. TAL effectors were discovered in the genus 
Xanthomonas, a plant pathogenic bacteria that uses these proteins to regulate DNA 
expression in host plant cells by binding the promoters of target genes. TALE proteins 
were found to have 12-27 tandem repeats of 33-35 amino acids, each repeat specifically 
binding one base of the targeted DNA sequence143.  The base preference of the repeats 
is specified by the 12th and 13th adjacent amino acid residues in each repeat, which are 
called ‘repeat-variable di-residue’ (RVD). A code specifies the target specificity of 
these RVDs whereby a repeat containing NI at the RVD position binds Adenine, NG 
binds Thymine, HD binds Cytosine, and NN/NK binds Guanine 144. The simplicity of 
this system enabled molecular biologists to manipulate the repeats to recognize any 
desired sequence in the genome.  
DNA editing at the genomic scale is possible with TALE nuclease (TALEN) proteins, 
which are designed to have a FokI restriction enzyme domain fused to the TALE DNA 
binding domain. TALEN proteins are designed as heterodimers that bind to DNA and 
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generate double-strand breaks (DSBs) in the spacer region between the two recognition 
sequences143.  
 
 
1.2.3. CRISPR Technology 
 
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-­‐‑
associated (Cas) systems are the adaptive immune defenses that are found in bacteria 
and archaea. In this system, short RNA is used to direct degradation of foreign nucleic 
acids (DNA/RNA). There are three types of CRISPR systems. Single effector enzyme 
(i.e. cas9) is used to cleave double-strand (ds) DNA in the Type II CRISPR systems. In 
contrast, multiple effectors are used in the type I and type III145. A The CRISPR system 
consists of a cluster of CRISPR-associated genes, noncoding RNAs, and a distinctive 
array of repetitive elements (direct repeats). There are short variable sequences that are 
derived from exogenous DNA targets, known as protospacers, between these repeats. A 
protospacer is always associated with a protospacer adjacent motif (PAM: 5′-NGG) 
within the DNA target. DSBs are created by the Cas9 nuclease 3 bp upstream of the 
PAM (Figure. 4.5). Type II CRISPR systems consist of: 1) the Cas9 nuclease; 2) the 
CRISPR RNA (crRNA) array, which encodes guide RNAs (gRNA); and 3) the 
auxiliary trans-activating crRNA (tracrRNA) that assists the processing of the crRNA 
array into discrete units. Artificially fusing crRNA and tracrRNA together creates 
chimeric, single-guide RNA (sgRNA) (which we use in this thesis). The RNA-guided 
Cas9 nuclease increases the efficiency of genome engineering in eukaryotic cells by 
specifying a 20-nt targeting sequence within its guide RNA146. Assembly of 
CRISPR/Cas9 enzymes is straightforward. Annealed single stranded oligonucleotides 
encoding the target gRNA with BbsI recognition sequences are cloned into the 
pSpCas9(BB) plasmid. The pSpCas9(BB) plasmid includes selection markers such as a 
puromycin resistance gene or a GFP gene to select transfected cells. The CRISPR-
Cas9/Cas9n system creates double strand breaks (DSBs) that are repaired by eukaryotic 
cells, either by non-homologous end joining (NHEJ) or by homology directed repair 
(HDR) in the presence of a homologous DNA sequences. NHEJ causes small insertions, 
deletions, or base substitutions (INDEL)146 (Figure. 4.6). The NHEJ pathway is error-
prone. The endogenous DNA repair machinery processes the ends of DSBs. During this 
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process, random INDEL mutations can occur at the site of junction so frame-shifts and 
premature stop codons arise if the target sequence is in a coding region of the genome. 
The HDR pathway requires a repair template in the form of either a plasmid with a 
sequence homologous to the target site or single-stranded DNA oligonucleotides (ss-
oligo)146,147. 
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2.  AIM OF THE STUDY 
 
 
 
p53 protein levels are tightly regulated in normal cells.  Cellular stresses, such as 
DNA double-strand breaks results in the stabilization and accumulation of p53 protein 
in the nucleus.  The p53 protein is a transcription factor that directly controls numerous 
genes that are related to cellular functions such as cell cycle arrest and apoptosis.  The 
p53 C-terminal regulatory domain is the target of several post-translational 
modifications (PTM); this helps cells to strictly regulate the p53 protein activity in basal 
conditions or under stress. 
The last exon of the C-terminus, which is investigated in detail in this study, is a 
subject of many PTMs.  We studied how endogenous p53 behaves when it lacks several 
amino acids in its C-terminus.  The C-terminal mutant (CTM) cells were obtained using 
genome engineering tools (TALEN proteins and the CRISPR/Cas9 system).  We found 
out that even a single amino acid deletion, which is R379 in this study, could cause a 
major difference in the transcription of many genes, and even in the doubling time of 
the CTM cell lines.  There are nuclear import/export sites on the p53 protein, but none 
has been reported in the C-terminus encoded by the last exon.  Unexpectedly, we found 
that a truncated p53 protein (Δ26/ Δ26) that lacks the last exon of the Tp53 gene, cannot 
translocate into the nucleus after genotoxic stress.  We assessed p53 protein expression 
(by western blot) in CTM cell lines.  We also examined the subcellular localization of 
mutant p53 proteins using confocal microscopy.  Both types of experiments indicated 
that the CTM cell line (Δ26/ Δ26) had a p53 nuclear accumulation defect under stress.  
We checked if the p53 protein could bind to its target DNA efficiently, using pull-down 
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experiments.  We identified differentially transcribed genes in p53 CTM cell lines by 
Quantitative RT PCR.  We also analyzed changes in cell growth rate by xCELLigence 
real time cellular analysis equipment.  To have a broader view of what happens in cells 
with mutated p53, we also conducted RNA sequencing (RNASeq) to compare the 
transcriptome of our CTM cell lines with wild type cells.  We demonstrated that p53 C-
terminus is crucial for the accumulation of p53 and some of its target proteins under 
stress conditions; we confirmed that p53 CTM cell doubling time increases in some of 
the mutants, perhaps pointing to the relationship between CTD and telomere length148.  
The p53 C-terminus controls DNA binding activity of the p53 protein, which we 
confirmed here.  Our RNASeq experiments indicate that p53 may be playing a role in 
ribosomal biogenesis by coordinately controlling ribosomal protein gene expression.   
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3.  MATERIALS AND METHODS 
 
 
 
3.1. Materials 
 
 
3.1.1. Chemicals 
 
All the chemicals used in this thesis are listed in Appendix A. 
 
 
3.1.2. Equipment 
 
All the equipment used in this thesis is listed in Appendix B. 
 
 
3.1.3. Buffers and Solutions 
 
Standard buffers and solutions used in the project were prepared according to the 
protocols in Sambrook et al., 2001. 
Agarose Gel: For 100 ml 1% w/v gel, 1 g of agarose powder was dissolved in 100 
ml 0.5X TBE buffer by heating.  0.01% (v/v) ethidium bromide was added to the 
solution. 
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Calcium Chloride (CaCl2) Solution: 60mM CaCl2 (diluted from 1M stock), 15% 
Glycerol, and 10mM PIPES (pH 7.00) were mixed and the solution was filter-sterilized 
and stored at +4°C. 
Blocking Buffer: For 10ml, 0.5 g skim milk powder was dissolved in 10 ml PBS. 
FACS Buffer: For 500ml 1X solution, 2.5 g bovine serum albumin (BSA) and 0.5 
g sodium azide were mixed in 500 ml 1X PBS and the solution was kept at +4°C. 
HEPES-buffered saline (HBS): For 100 ml 2X solution 0.8 g NaCl, 0.027 g 
Na2HPO4.2H2O and 1.2 g HEPES were dissolved in 90 ml of ddH2O.  pH was 
adjusted to 7.05 with 0.5 M NaOH and the solution was completed to 100 ml with 
distilled water.  The buffer was filter-sterilized and stored at -20°C. 
PBS-Tween20 (PBST) Solution: For 1 L 1X solution, 0.5 mL Tween20 was 
added in 1 L 1X PBS. 
Phosphate-buffered saline (PBS): For 200 ml 1X solution, 1 tablet of PBS 
(Sigma P4417) was dissolved in 200 ml ddH2O and the solution was filter-sterilized. 
Polyethylenimine (PEI) Solution: For 1 mg/ml solution, 100 mg 
polyethylenimine powder was dissolved in 100 ml ddH2O and the pH was adjusted to 
7.0 with HCl.  The solution was filter sterilized and kept at -20°C. 
Protein Loading Buffer: Commercial buffer (Fermentas #R0891) that includes 
5X loading dye (0.313 M Tris HCl (pH 6.8 at 25°C), 10% SDS, 0.05% bromophenol 
blue, 50% glycerol) and 20X reducing agent (2 M DTT) were mixed. 
SDS Separation Gel: For 10ml 13% gel, 2.5 ml Tris (1.5M pH 8.8), 3 ml H2O, 
4.34 ml Acryl: Bisacryl (30%), 100 µl 10% SDS, 100 µl 10% APS, and 10 µl TEMED 
were mixed. 
SDS Running Buffer: For 1 L 10X stock solution, 30.3 g Tris base, 144 g 
Glycine, and 10 g SDS were dissolved in 1L ddH2O. 
SDS Stacking Gel: For 5 ml 4% gel, 1.25 ml Tris (0.5 M pH 6.8), 2.70 ml H2O, 1 
ml Acryl-Bisacryl (30%), 50 µl 10% SDS, 15 µl 10% APS, and 7.5 µl TEMED were 
mixed. 
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Transfer Buffer: For 1 L 10X stock solution, 14.5 g Tris and 72 g Glycine was 
dissolved in 1 L ddH2O.  Final pH was adjusted to 8.3.  
Transfer Buffer: For 800 ml 1X, 80 ml 10X Transfer Buffer, 160 ml methanol, 
and 560 ml ddH20 were mixed. 
Tris-Borate-EDTA (TBE) Buffer: For 1 L 10X stock solution, 104 g Tris-base, 
55 g boric acid, and 40 ml 0.5M EDTA (pH 8.0) were dissolved in 1 L of ddH2O.  The 
solution is kept at room temperature. 
Blocking solution: 5% skimmed milk in 1X PBS  
Antibody dilution solution: 0.5% 100 Triton X – 100 with 1% BSA in 1X PBS 
Propidium Iodide (PI) staining solutions: Propidium iodide (1mg/ml), 60µl 
Triton X-100 and 100µl RNAse (stock: 10mg/ml) and the volume were adjusted to 10 
ml with cold FACS incubation buffer.    
 
 
3.1.4. Growth Media 
 
Luria Broth (LB): For 1 L 1X LB media, 20 g LB powder was dissolved in 1 L 
ddH2O and then autoclaved at 121°C for 15 minutes.  For selection, kanamycin at a 
final concentration of 50 µg/ml or ampicillin at a final concentration of 100 µg/ml was 
added to liquid medium just before use. 
LB-Agar: For 1 L 1X agar medium, 20 g LB powder and 15 g bacterial agar 
powder were dissolved in 1 L ddH2O and then autoclaved at 121°C for 15 minutes.  
Autoclaved medium was poured onto sterile Petri dishes after cooling down to 50°C.  
For selection, kanamycin at a final concentration of 50 µg/ml or ampicillin at a final 
concentration of 100 µg/ml was added to the medium before pouring onto petri dishes.  
Sterile solid agar plates were kept at 4°C for maximum 3 month. 
DMEM: HEK293T, HCT116 (HCT116WT), and HCT116p53-/- (HCT116KO) 
cell lines were maintained in filter-sterilized DMEM that is supplemented with 10% 
heat-inactivated fetal bovine serum, 2mM L-Glutamine, 100 U/ml penicillin and 100 
U/ml streptomycin. 
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Freezing medium: All the cell lines were frozen in heat-inactivated fetal bovine 
serum containing 10% DMSO (v/v). 
 
 
3.1.5. Commercial Molecular Biology Kits 
 
• QIAGEN Plasmid Midi Kit, 12145, QIAGEN 
• QIAGEN Plasmid Maxi Kit, 12163, QIAGEN 
• Qiaprep Spin Miniprep Kit, QIAGEN 
• Qiaquick Gel Extraction Kit, 28706, QIAGEN 
• Qiaquick PCR Purification Kit, 28106, QIAGEN 
• RevertAid First Strand cDNA Synthesis Kit, K1622, FERMENTAS  
• SuperScript Double-Stranded cDNA Synthesis Kit, 11917-020, INVITROGEN 
• Golden Gate TALEN and TALE Effector kit 2.0, Addgene #1000000024 
• TOPO® TA Cloning Kits, Thermo Fisher Scientific 
• LightCycler® 480 SYBR Green I Master, Roche 
 
 
3.1.6. Enzymes 
 
All the restriction enzymes, DNA modifying enzymes and polymerases and their 
corresponding buffers used in this study were from either Fermentas or NEB.   
 
 
3.1.7. Bacterial Strains 
 
Escherichia coli DH-5α (F- endA1 glnV44 thi-1 relA1 gyrA96 deoR nupG 
lacZdeltaM15 hsdR17) competent cells were used for bacterial transformation of 
general plasmid DNAs.   
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3.1.8. Mammalian Cell Lines 
 
HEK293T: Derivative of human embryonic kidney 293 (HEK293) cell line that 
stably express the large T antigen of SV40 virus (ATCC: CRL-1573™). 
HCT116 and HCT116p53-/-: Human colorectal carcinoma cell line and its p53-
null derivative (ATCC CCL-247™) 
 
 
3.1.9. Plasmids and Primers 
 
The plasmids and the primers used in this thesis are listed in Table 3.1 and Table 
3.2, respectively. 
PLASMID NAME PURPOSE OF USE SOURCE 
PCDNA Transfection efficiency 
Control  
Lab Construct 
pHD1 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pHD2 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNI3 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNI4 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNI5 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNI6 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNI7 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
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pNN8 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNN9 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNN10 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNG1 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNN4 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pHD5 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pHD6 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pLR-NG TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNN1 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNG2 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pHD3 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNG4 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNG5 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNN6 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
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pNI7 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNI8 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pHD9 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNI10 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNG1 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNN2 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNN4 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pNG5 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pLR-NN TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pFUS_A TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pFUS_B6 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pFUS_B7 TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pC-GoldyTALEN TALEN Cloning Golden Gate TALEN 
Kit #1000000024 
pSpCas9(BB)-Puro CRISPR Cloning Zhang Lab 
pSpCas9n(BB)-Puro CRISPR Cloning Zhang Lab 
	   27	  
PTZ57 R/T Sequencing InsTAclone PCR cloning 
kit 
 
Table 3.1: The list of the plasmids used in this thesis.  Plasmid names, their purpose of 
uses and sources are given. 
PRIMER 
NAME 
SEQUENCE PURPOSE 
OF USE 
h_p21rt_FW
D 
GCAGACCAGCATGACAGATTT p21 qPCR 
h_p21rt_rev GGATTAGGGCTTCCTCTTGGA p21 qPCR 
puma fwd ACCAGCCCAGCAGCACTTAG PUMA qPCR 
puma rev TCTTCTTGTCTCCGCCGCTC PUMA qPCR 
gapdh fwd TCCTGCACCACCAACTG GAPDH 
qPCR 
gapdh rev TCTGGGTGGCAGTGATG GAPDH 
qPCR 
p53_GADD
45_fwd 
(Biotin)GAACATGTCTAAGCATGCTG Pull down 
p53_GADD
45_rev 
(Biotin)CAGCATTCTTAGACATGTTC Pull down 
GAPDH-
FWD-long 
GTCAAGGCTGAGAACGGGAAG RNA-
sequencing 
quality 
control 
GAPDH-
REV-long 
GTCAAAGGTGGAGGAGTGGGT RNA-
sequencing 
quality 
control 
beta_actin-
FWD-long 
GTTGGGGGACAAAAAAGGGGGA RNA-
sequencing 
quality 
control 
beta_actin-
REV-long 
TCTTCATTGTGCTGGGTGCC RNA-
sequencing 
quality 
control 
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p53K381A_
Fwd primer 
ACCTCCCGCCATAAAGCACTCATGTTCAAGA
C 
 
PCR 
p53K381A_
Rev primer 
AGACTGACCCTTTTTGGACTTCAGGTGG PCR 
TP53-for CCCCAGCCCCCTAGCAGAGA PCR 
TP53-rev CAGGAAGCCAAAGGGTGAAGAGG PCR 
Tp53- long 
primer-fwd 
ATCCTCCTCCCCACAACAAAACACC PCR 
Tp53- long 
primer-rev 
TCTCTCCTCCCTGCTTCTGTCTCCT PCR 
ss oligo-HR 
Tp53 
 
 
AAAGGGTCAGTCTACCTCCCGCCATAAAAAG
CTTATGTTCAAGACAGAAGGGCCTGACT 
HDR 
hp53 fwd CCCAAGCAATGGATGATTTGA qPCR 
hp53 rev GGCATTCTGGGAGCTTCATCT qPCR 
Cas9 p53-
fwd 
CACCGCATGAGTTTTTTATGGCGGG CRISPR/Cas9 
design 
Cas9 
p53K382rev 
AAACCCCGCCATAAAAAACTCATGC CRISPR/Cas9 
design 
Left Cas9n 
p53-fwd 
CACCGGGAGGTAGACTGACCCTTTT 
 
CRISPR/Cas9
n design 
Left Cas9n 
p53- rev 
AAACAAAAGGGTCAGTCTACCTCCC 
 
CRISPR/Cas9
n design 
Right 
Cas9n- fwd 
CACCGAAACTCATGTTCAAGACAGA 
 
CRISPR/Cas9
n design 
Right Cas9n 
p53K382rev 
AAACTCTGTCTTGAACATGAGTTTC CRISPR/Cas9
n design 
pJET1.2 
Forward 
CGACTCACTATAGGGAGAGCGGC Pre-
Sequencing 
control 
pJET1.2 
Reverse 
AAGAACATCGATTTTCCATGGCAG Pre-
Sequencing 
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 control 
Dkc1-FWD CTCGGAAGTGGGGTTTAGGT qPCR 
Dkc1 REV ACCACTTCAGCAACCACCTC qPCR 
hTERT 
FWD 
TGTACTTTGTCAAGGTGGATGTGA qPCR 
hTERT 
REV 
TTGATGATGCTGGCGATGA qPCR 
Rtel1 FWD GCCAGGGAGCTACATCTTTG qPCR 
Rtel1 REV CCCTTGGTCTGAAACGTGAT qPCR 
Terf1 FWD GCAACAGCGCAGAGGCTATTATT qPCR 
Terf1 REV AGGGCTGATTCCAAGGGTGTAA qPCR 
 
Table 3.2: The list of the primers used in this thesis.  Primer names, their sequences, 
and their purpose of uses are given.   
 
 
3.1.10. DNA and Protein Molecular Weight Markers  	  
DNA ladders and protein molecular weight markers used in this thesis are listed 
in Appendix C.   
 
 
3.1.11. DNA Sequencing  	  
McLab (CA-USA) commercially provided sequencing service.  
(http://www.mclab.com/) 
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3.1.12. Software, Computer-Based Programs, and Websites  
 
The software and computer based programs used in this project are listed in 
Table 3.3  
SOFTWARE, 
PROGRAM, 
WEBSITE NAME  
COMPANY/WEBSITE ADDRESS  PURPOSE OF 
USE 
NCBI BLAST  Htpp://blast.ncbi.nlm.nih.gov/Blast.cgi  
 
Basic local 
alignment search 
tool  
FlowJo V10 Tree Star Inc.   
 
Viewing and 
analyzing flow 
cytometry data  
ImageJ  http://imagej.nih.gov/ij/  
 
Visualizing and 
calculating p53 
amount in WT cells 
versus CTM cell 
lines/ Comparing 
western blot band 
intensities 
CLC Main 
Workbench  
CLC bio  
 
 Genomics and 
Transcriptome 
analysis 
Ensembl Genome 
Browser  
http://www.ensembl.org/index.html  
 
Human and mouse 
genome  
LightCycler 480 SW 
1.5  
ROCHE  Analyzing qPCR 
results  
RTCA Software 2.0  ACEA Biosciences  
 
Real-time cell 
growth analysis  
CRISPR design http://crispr.mit.edu/ CRISPR designer 
Visual Molecular 
Dynamics 
http://www.ks.uiuc.edu/Research/vmd/ Display and 
analyzing TALEN 
proteins 
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NAMD-Scalable 
Molecular 
Dynamics 
http://www.ks.uiuc.edu/Research/namd/ Stimulation of 
TALEN proteins 
 
Table 3.3: The list of the software, programs and websites used in this thesis.  Name of 
the software, programs, and websites, their producers/websites and purpose of uses are 
given.   
 
 
3.2. Methods 
 
 
3.2.1. Bacterial Cell Culture 
 
Bacterial Culture Growth: Escherichia coli (E.  coli) DH5α strain was grown in 
Luria Broth (LB) or 2XLB (low salt), overnight at 37°C, shaking at 250 rpm.  For long- 
term storage of bacterial cells, glycerol was added to the overnight grown culture to a 
final concentration of 10% in 1 mL in a cryo-vial.  Bacterial glycerol stocks were stored 
at -80°C.  In order to obtain single colonies, bacteria were spread on LB/agar containing 
petri dishes using glass beads and incubated overnight at 37°C without any shaking.  All 
growth media were supplemented with or without selective antibiotic prior to any 
application.   
Preparation and Transformation of Competent Bacteria: A single colony of 
E.coli DH5α was picked from an LB/agar petri dish (incubated overnight without any 
antibiotic selection).  The colony was inoculated in 50 mL LB without any selective 
antibiotics in a 200 mL flask and incubated at 37°C overnight, shaking at 250 rpm.  The 
next day, 4 mL from this overnight culture was diluted in 400 mL LB medium in a 2 L 
flask and incubated at 37°C overnight, shaking at 250 rpm until the optical density (at 
590 nm) reached 0.375.  The culture was then transferred into 50 ml polypropylene 
tubes (8 tubes in total) and incubated on ice for 10 min, followed by a centrifugation at 
1600 g for 10 min at 4°C.  After centrifugation, each pellet was resuspended in 10 mL 
ice-cold CaCl2 solution and centrifuged at 1100 g for 5 min at 4°C.  The pellets were 
again resuspended in 10mL ice-cold CaCl2 solution and incubated on ice for 30 min.  
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Following the final centrifugation at 1100 g for 10 min at 4°C, this time the pellets were 
resuspended in 2mL ice-cold CaCl2 solution and pooled in a single polypropylene tube 
(16 ml bacterial solution in total).  This solution was dispensed into 200µL aliquots into 
pre-chilled 1.5ml centrifuge tubes.  Competent cells were frozen immediately in liquid 
nitrogen and then stored at -80°C for later use.  Transformation efficiency of the 
competent cells (typically 107-108 cfu/µg) was tested by pUC19 plasmid 
transformation, using different concentrations of the plasmid DNA.   
Chemically competent cell was taken out from -80°C and mixed with 100 pg of 
plasmid DNA.  The cells were then incubated on ice for 30 min.  After the incubation 
period, the cells were heat shocked for 90 s at 42°C and transferred back on ice for 60 s.  
800 µL of LB (without any antibiotics) was added on the cells and this culture was 
incubated for 45 min at 37°C.  After 45 min, the cells were spread with glass beads on 
LB/agar petri dishes containing appropriate antibiotic for selection.  The plate was 
incubated overnight at 37°C without any shaking.   
Plasmid DNA Isolation: Plasmid DNA isolation was performed using either the 
alkaline lysis protocol from Molecular Cloning: A Laboratory Manual (Sambrook et al) 
or Qiagen Mini-Midiprep Kits according to the manufacturer protocols.  The 
concentration and purity of the DNA isolated were determined by using a UV- or a 
NanoDrop- spectrophotometer.   
 
 
3.2.2.  Plasmid Construction 	  
Polymerase Chain Reaction (PCR): Optimized PCR conditions are shown in 
Table 3.4 The thermal cycler conditions were as follows: initial denaturation at 95°C for 
5 min followed by 30 (or 35) cycles of denaturation step (at 95°C, for 30 seconds), 
annealing step (at a temperature specific for every primer pair, for 30 seconds) and an 
extension step (at 72°C, for 1 min for every 1 kilo base of DNA).  These cycles were 
then followed by a final extension step at 72°C for 10 min. 
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PCR Reaction Volume Final Concentration 
Water- Nuclease free Up to 25 µl - 
10X PCR buffer - MgCl2 2.5 µl 1 X 
50 µM MgCl2 0.75 µl 1.5 mM 
10 mM dNTP mix 0.5 µl 0.2 mM each 
10 µM Forward primer 0.5 µl 0.2 µM 
10 µM Reverse primer 0.5 µl 0.2 µM 
Template DNA Variable  <500 ng 
Platinum™ Taq DNA 
Polymerase 
0.1 µl 2 U/rxn 
 
Table 3.4: Optimized PCR conditions 
Restriction Enzyme Digestion: Restriction enzyme digestion reactions were 
performed by mixing the required amount of DNA with the desired enzymes and their 
compatible buffers in 1.5 mL centrifuge tube, followed by incubation in a water-bath set 
to a temperature optimum for the enzymes for a duration of 2 hours.  For diagnostic 
digestions 1µg of DNA was used.  10µg or more DNA was digested for gel extraction 
and cloning purposes.  If the plasmid DNA was digested with a single restriction 
enzyme and was planned to be used in a ligation reaction, then the linear plasmid was 
dephosphorylated by calf intestinal alkaline phosphatase (CIAP) enzyme for an 
additional 45 min at 37°C.   
Agarose Gel Electrophoresis: PCR products, digestion reaction products and 
other DNA samples were separated and visualized by agarose gels.  Gels were prepared 
by dissolving the required amount of agarose (ranging from 0.5 g to 3 g depending on 
the sizes of the DNA fragments in the samples) in 100mL 0.5X TBE.  In order to fully 
dissolve the agarose, the mixture was heated in a microwave oven.  The solution was 
then cooled down and 2µl of ethidium bromide was added.  After mixing properly, the 
gel was cast in a gel apparatus and cooled down and solidified.  DNA samples were 
mixed with DNA loading dye were loaded into the gel, which was run at 100V for 75 
min in 0.5X TBE and the bands were visualized using UV light on a Biorad Imager.  
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Desired DNA bands were excised from the gel and extracted using a Qiagen Gel 
Extraction Kit according to the manufacturer protocol.   
Ligation: Ligation reactions were performed by using T4 DNA Ligase, in 1:3, 
1:5 or 1:10 vector versus insert ratio, using 50 ng of the plasmid DNA.  Ligation 
reactions were incubated at 16°C for overnight.  The next day, the ligation mixture was 
transformed into chemically competent DH5α bacteria and plated onto antibiotic 
selective-LB/agar petri dishes and incubated at 37°C.   
 
 
3.2.3.  Mammalian Cell Culture  	  
Maintenance of Cell Lines: HEK293T, HCT116, and HCT116p53-/- cell lines 
were maintained in DMEM medium in tissue culture plates in an incubator set to 37°C 
with 5%CO2.  When the confluency of the cells reached over 80%, the cells were split 
into pre-warmed, fresh medium with a ratio of 1:10.  In order to freeze cells for later 
use, cells at the exponential growth phase were resuspended in ice- cold freezing 
medium and transferred to cryovials.  Tubes were stored at -80°C for at least 24 h and 
then transferred to liquid nitrogen tank for long- term storage.  After thawing the cells, 
they were immediately washed with growth medium to remove any residual DMSO.   
Transient Transfection of Cell Lines Using Polyethylenimine (PEI): One day 
before the transfection, 1-3 x 106 cells were split onto 10 cm tissue culture plates.  On 
the day of the transfection, 10 µg of plasmid DNA was mixed in 1 mL serum-free 
DMEM in a sterile micro centrifuge tube.  PEI (1µg/µl) was added to the DNA-DMEM 
mix at a 3:1 ratio of PEI (µg) to total plasmid DNA (µg) and mixed immediately by 
vortexing.  After 15 minutes of incubation at room temperature, the mixture was added 
drop wise on the cells.   
Cell Lysis, SDS Gel, Transfer and Western-Blot: Cells were harvested from 
their cell culture plates either using trypsin or a cell scraper.  Cells were centrifuged at 
1000 rpm for 5 min and the supernatant was discarded.  The cells were washed once 
with 1X PBS and the pelleted again.  The pellet was dissolved in an appropriate amount 
of protein loading buffer and the mixture was boiled at 95°C for 10 min.  The lysates 
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were either kept at -80°C for later use or used immediately.  The SDS gels used in this 
project had a 10% separating part and a 4% stacking part.  After the samples were 
loaded into the SDS gels, the gels were run with 1X running buffer at 80 V (constant 
voltage) for 1.5 - 2 h using a BIORAD Mini Protean Tetra Cell.  After running, the gels 
were transferred to 0.45 µm PVDF membranes (Thermo Scientific) in 1X transfer 
buffer at 250 mA (constant current) for 1.5 h at 4°C using BIORAD Mini Trans-blot.  
Membranes were then blocked in 10 mL PBST - milk at room temperature for 1 hour 
with constant shaking.  Primary antibody incubations were done overnight at 4°C and 
secondary antibody incubations were done for 1 hour at room temperature.  After 
incubation, membranes were washed with PBST 3 times for 10 min each.  After the 
final washing step, the membranes were incubated with an enhanced chemiluminescent 
substrate for 5 min at room temperature in the dark room and exposed to X-Ray films 
(Fuji); ImageQuant™ LAS4000 Biomolecular imager could also analyze membrane 
directly. 
 
 
3.2.4.  TALEN Protein Assembly 	  
TALEN Target Site: The software used for design of transcription activator 
like effectors (TALE) and transcription activator like effector nucleases (TALEN) is 
available online (TAL Effector Targeter; https://tale-nt.cac.cornell.edu/).  DNA 
sequence entered is scanned for potential TALEN recognition sites based on either 
preset design guidelines defined by four different articles or user-provided spacer and 
RVD lengths.  The software gives coordinates and sequences of recognition sites for 
right and left TALEN monomers and the spacer sequence.  In addition, RVD sequences 
necessary for construction of custom TALENs were also provided as software output. 
Golden Gate Assembly: TAL effector DNA binding domain is composed of 
tandem repeat modules.  12th and 13th amino acids within each repeat module, called 
repeat-variable di-residues (RVDs), are responsible for nucleotide recognition.  NI, NN, 
NG and HD are the four most common RVDs, each preferentially bind to nucleotides 
A, G, T, and C, respectively (Figure.  4.1).  Design of custom TALENs were performed 
using TALEN Golden Gate Kit, which was obtained from Addgene.  The Golden Gate 
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TALEN kit, reported by Cermak et al (2011), contains a set of module plasmids with 
each individual RVDs, array plasmids for intermediate cloning, and backbone 
expression plasmids to make final TALEN expression constructs. 
The custom TALEN is assembled using successive rounds of Golden Gate 
cloning, in which digestion by restriction endonucleases such as BsaI and Esp3I is 
performed to create unique 4 bp overhangs on DNA fragments.  These unique 
overhangs flanking each RVD were designed such that up to 10 RVD-encoding repeat 
module plasmids can be ligated in a single reaction.  The desired array is cloned into a 
final expression vectors.  Construction of TALEN construct was achieved in 5 days.  
All cloning and assembly procedure was performed exactly according to Cermal et al.  
Golden Gate Cloning protocol.   
 
 
3.2.5.  CRISPR/Cas9 and CRISPR/Cas9n Gene Editing 	  
CRISPR guide RNA selection: CRISPR/Cas9 system could be designed 
against almost any desired target site; the only limitation is the presence of protospacer 
adjacent motive (PAM) sequence (5’ NGG 3’) down stream of the target region.  We 
used an online tool to find CRISPR targets with the highest score, meaning those that 
have the lowest number of off-targets in the coding-sequence and other regions of the 
while genome.  (http://crispr.mit.edu/). 
Preparing CRISPR/Cas9 and CRISPR/Cas9n plasmid: After selecting the 
best possible CRISPR target on the region of interest, guide RNA oligonucleotides were 
obtained commercially as top and bottom strand, from Midland Certified Reagent Co.  
(midland, TX).  These oligonucleotides consist guide RNA and BbsI overhangs at the 5’ 
end of each of oligonucleotides.  These oligonucleotides are then annealed and double 
stranded guide RNA is then cloned into mammalian expression pSpCas9(BB)-Puro (or 
pSpCas9n(BB)-Puro)  plasmid (Figure4.3).  All the plasmid preparation procedure is 
according to Ann Ran et al. protocol (Nature protocols, 2013). 
CRISPR gene editing procedure: Final CRISPR/Cas9 or Cas9n constructs are 
transfected into the HEK293 and HCT116 using PEI transfection method.  If a specific 
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mutation is considered, a single stranded oligo nucleotide (ss-oligo) with our desired 
mutation in its sequence is also co-transfected.  24h post-transfection Puromycin 
selection was applied to enrich transfection efficiency by creating a selective medium 
for transfected cells.  Cells stay in Puromycin selection medium for at least 72h.  After 
transfection enrichment, cells are grown in normal DMEM until the number of cells is 
sufficient for DNA extraction and single cell clone screening, a 1-day recovery is 
normally sufficient.  The remaining procedure is the same for TALEN proteins and 
CRISPR transfected cells.  Each single cell clone is screened by RFLP assay.   
 
 
3.2.6.  RNA-Sequencing 	  
RNA Sequencing: HCT116WT, mut#4, mut#5, and mut#9 p53 CTM cell lines 
were either untreated or treated with 1µM doxorubicin for 24 hours.  Total RNA was 
extracted, polyA selected and triplicate samples were sequenced at Beijing Genomics 
Institute on an Illumina HiSeq 2000 sequencing machine and analyzed using the R 
library DEseq.  To identify biological processes influenced by CTM p53, further 
analysis on RNA sequencing results is ongoing.    
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4.  RESULTS 
 
 
 
4.1.  Screening Homozygous CTM Cell Lines Created by Genome Editing Tools 
 
 
In this study, we tried to characterize the p53 C-terminal regulatory domain by 
creating several p53 C-terminal mutant (CTM) human colon cancer cell lines.  We 
identified the phenotypic differences between wild type p53 expressing and CTM p53 
expressing HCT116 cells.   
Here we describe three different homozygous mutant HCT116 human colon cancer 
cell lines that have mutations in the exon encoding the C-terminus of their Tp53 gene in 
detail.  Genome editing tools were used to create these mutants.  We studied the 
properties of the endogenously expressed mutant p53 protein, by examining its 
expression, nuclear accumulation, DNA binding, protein interaction, ability to activate 
downstream genes and its influence on cell growth.  The first step was to design 
genome-editing tools to create p53 CTM HCT116 cell lines.  We first generated 
transcription activator like effector nuclease (TALEN) proteins targeting the last exon 
of the Tp53 gene (Figure 4.1).  Next we switched our genome editing methodology to 
CRISPR/Cas9 technique. 
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4.1.1. TALEN-Mediated CTM Cell Lines 	  
We first attempted to mutate the p53 gene using TALENs by expressing pairs of 
TALEN proteins targeting the last exon of this gene.  We constructed a pair of TALEN 
protein expressing plasmids containing the correct sequence of repeats that would bind 
the desired sequence in the p53 gene using the protocol developed by Cermak et al.143.  
These two TALEN proteins were designed to bind to the top and bottom strands of the 
p53 gene exon 11 with a spacer of 15 base pairs.  To generate expression constructs, we 
cloned TALEN repeats in the required order, into the final mammalian expression 
plasmid (pC-GoldyTALEN).  After confirming the sequence of the TALEN expression 
constructs, we transfected HCT116 human colon cancer cell lines.  To determine the 
transfection efficiency, we assessed the percentage of cells that express a GFP protein 
using fluorescent microscopy and by flow cytometry after transfecting cells with the 
pcDNA GFP plasmid (Figure 4.2).  After transfecting cells with TALEN expression 
constructs, we generated single cell clones; PCR amplified the region of interest from 
genomic DNA and assessed mutation efficiency by RFLP and by sequencing.  We made 
several attempts to obtain homozygous mutants with the TALEN method, but were not 
successful (Figure 4.2 and 4.3).    
As an alternative option for a genome-engineering tool, we decided to use the 
CRISPR/Cas9 genome engineering system to target the p53 gene.  Because the steps of 
generating single cell clones and assessment of mutation efficiency by RFLP are very 
similar between the TALEN and CRISPR/Cas9 methods and are described in detail 
below and because our attempts to generate homozygous mutant generation failed, our 
work on TALENs are not further described in detail here.   
CTM cell lines were detected using the RFLP assay.  As it is shown in figures 4.1 and 
4.4, exactly at the site of TALENs and CRISPR binding regions, there is a FauI 
restriction site, which would be destroyed, in case genome-editing tools work.  The 
results of the RFLP assay can be seen in figure 4.7.  The intensity of any remaining 
uncut PCR bands in amplicons derived from TALEN proteins and CRISPR/Cas9 
transfected cells after the digestion indicate the approximate percentage of the mutated 
cells in the transfected pool.  For TALEN transfected cells, the efficiency of the 
TALEN-induced DSB was low in comparison with the CRISPR system (Figure 4.3) 
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Figure	  3	  
 
 
 
 
 
 
 
 
 
a)#
b)#
Figure. : TALEN proteins designed to 
create P53 CTD mutant cells. a) Left and 
right TALEN proteins are shown in dark 
red. The last exon’s coding sequence is 
represented in yellow and its translation is 
mentioned. FauI cut site is shown in red; it 
is used for RFLP assay. b) an illustration of 
TALEN proteins, binding to the last exon of 
the p53 protein. 12th and 13th amino acid of 
each repeat bind to a specific nucleotide on 
the target region. b) Illustration od TALEN 
proteins on the Tp53 gene’s last exon. 
TALEN protein consists of an N-terminal 
tail, a DNA-binding domain, and C-
terminal to which FokI endonuclease 
enzyme is attached (all shown in orange); 
each of FokI endonucleases introduce a 
nick in the DNA strand they bind. Each 
repeat of DNA-binding domain of the 
TALEN proteins are shown in a color-
coded circle. Protein sequence o each 
repeat in magnified and 12th and 13th RVD 
that differs in each repeat to bind to specific 
nucleotide, is shown in dark blue.   
A NI 
T NG 
C HD 
G NN 
LTPEQVVAIASNIGGKQALETVQRLLPVLCQAHG/
k/
CCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGA 
GGTGGACTTCAGGTTTTTCCCAGTCAGATGGAGGGCGGTATTTTTTGAGTACAAGTTCTGTCTTCCCGGACTGAGTCTGACT 
FokI&
FokI&
DNA binding domain 
b) 
Figure 4.1: TALEN proteins designed to create P53 CTD mutant cells.  a) 
Left and right TALEN proteins are shown in dark red.  The last exon’s 
coding sequence is represented in yellow and its translation product is 
shown.  The FauI cut site used for the RFLP assay is shown in red.  b) 
Illustration of TALEN proteins on the Tp53 gene’s last exon.  TALEN 
protein consists of an N-terminal tail, a DNA-binding domain, and a C-
terminal domain to which FokI endonuclease enzyme is attached (all shown 
in orange); each of the FokI endonucleases introduce a nick in the DNA 
strand they bind.  Each repeat of DNA-binding domain of the TALEN 
proteins are shown in a color-coded circle.  Protein sequence of each repeat 
is magnified and the 12th and 13th RVD that differs in each repeat to bind to 
specific nucleotide is shown in dark blue.  NN repeat binds to Guanine 
nucleotide, shown in orange; NG binds to Thymine, shown in gray; HD 
binds to Cytosine in purple; NI binds to Adenine, shown in blue.   
 
a) 
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Figure	  4	  
Figure 4.2: Determination of transfection and RFLP efficiency.  Cells were transfected 
with pcDNA GFP plasmids and RFLP analysis was performed on TALEN transfected 
cell pools.  a) On the left, HCT116 human colon cancer cells were imaged using the 
phase contrast technique on a fluorescent microscope.  On the right, the same cells were 
imaged using a green fluorescent filter; green fluorescent cells correspond to those 
transfected successfully with the pcDNA GFP plasmid.  b) Analysis of transfected cells 
using flow cytometry indicates transfection efficiency 73.1% for HCT116WT cells.  
Cell viability was determined by staining with 7AAD. c) RFLP analysis. A 300 bp PCR 
band was digested with the FauI restriction enzyme and generates two bands of size 
~270 and ~30 bp.  We conclude that TALEN transfected pools have a low mutation rate 
because the amount of uncut DNA after RFLP is not detectable.   
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Figure	  5 
Figure 4.3: Identification of heterozygous mutants from single cell cloned TALEN 
transfected pools.   a) Several single cell clones were screened by RFLP to find mutant 
clones; here several WT and one (clone #8) heterozygous mutant are shown.  b) Clone 
#8 is diluted for the 2nd time to figure out if the clone is heterozygous or is actually 
coming from two clones, one WT, the other mutant. Three heterozygous mutants are 
shown after an RFLP screening of clone #8, diluted for the second time.  PCR product 
from the WT allele of clone #8 gets cut, but other mutant allele stays intact after the 
digestion, indicating the heterozygousity of this clone.  	  
  	  
 
 
4.1.2.  CRISPR-Mediated CTM Cell Lines 	  
As an alternative to the TALEN mediated genome engineering, we designed 
CRISPR/Cas9 and CRISPR/Cas9n plasmids against the last exon of the Tp53 gene 
(Figure 4.3).  To do this, we followed the protocol of Ran et al146.  This method 
expresses both the guide RNA component and the Cas9 cDNA from a single plasmid 
that can be transfected into eukaryotic cells.  To generate CRISPR/Cas9 plasmids 
targeting the Tp53 gene, we annealed oligonucleotides encoding the top and bottom 
strands of the guide RNA (Figure 4.5) and cloned these into the pSpCas9(BB)-puro 
plasmid (Figure 4.5).  This plasmid includes: U6 promoter, CBh promoter (an altered 
version of CAG promoter), 3X FLAG epitope gene, nuclear localization signal (NLS), 
Cas9 restriction enzyme gene from S. pyogenes (SpCas9), 2A peptide self-cleaving 
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Figure. : Electrophoresis gel figure of RFLP 
experiment of CRISPR/Cas9 and CRISPR/
Cas9n transfecetd cells; a) HCT116WT cells are 
transfected with CRISPR/Cas9 and CRISPR/
Cas9n plasmids. DNA of the transfecetd pool is 
extracted and the target region is amplified by 
PCR (on the right); the transfecetd pool is 
digested with FauI restriction site (shown on the 
left). DNA ladder is shown in the middle of the 
gel. RFLP (restriction fragment length 
polymorphism) method is used to figure out if 
the FauI site is intact or is destroyed due to 
CRISPR/Cas9 activity. The 3rd line on the left 
shows a faint band (in the white rectangle) 
which represents the PCR product from the 
mutated cells that do not have FauI site. b) The 
faint un-cut bands are sequenced to see various 
mutations in the pool of transfected cells. On the 
left, random mutations created by CRISPR/Cas9 
system is shown. On the right, several different 
deletions in CRISPR/Cas9n system are 
presented. 
FauI%digested%
1% 2% 3% 4% 5% 6% 7% 8% 9% 10
%
W
T%
1B
un
cu
t%
La
dd
er
%
Figure. : Single cell clone screening. a) several single cell clones are  
screened by RFLP to find mutant clones; here several WT and one (colony 
no 8) heterozygous mutants are shown. b) Colony no 8 is diluted for the 2nd 
time to figure out if the clone is heterozygous, or is actually coming from 2 
clones, one WT, other one mutant; three heterozygous mutants are shown 
after an RFLP screening of clone no 8. PCR product from the WT allele of 
clone no 8 gets cut, but other mutant allele cannot be cut with the enzyme.  
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Figure. : Electrophoresis gel figure of RFLP 
experiment of CRISPR/Cas9 and CRISPR/
Cas9n transfecetd cells; a) HCT116WT cells are 
transfected with CRISPR/Cas9 and CRISPR/
Cas9n plasmids. DNA of the transfecetd pool is 
extracted and the target region is amplified by 
PCR (on the right); the transfecetd pool is 
digested with FauI restriction site (shown on the 
left). DNA ladder is shown in the middle of the 
gel. RFLP (restriction fragment length 
polymorphism) method is used to figure out if 
the FauI site is intact or is destroyed due to 
CRISPR/Cas9 activity. The 3rd line on the left 
shows a faint band (in the white rectangle) 
which represents the PCR product from the 
mutated cells that do not have FauI site. b) The 
faint un-cut bands are sequenced to see various 
mutations in the pool of transfected cells. On the 
left, random mutations created by CRISPR/Cas9 
system is shown. On the right, several different 
deletions in CRISPR/Cas9n syste  ar  
presented. 
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Figure. : Single cell clone screening. a) several single cell clones are  
screened by RFLP to find mutant clones; here several WT and one (colony 
no 8) heterozygous mutants are shown. b) Colony no 8 is diluted for the 2nd 
time to figure out if the clone is het rozygous, or is actually coming from 2 
clones, one WT, other one mutant; three heterozygous mutants are shown 
after an RFLP screening of clone no 8. PCR product from the WT allele of 
clone no 8 gets cut, but other mutant allele cannot be cut with the enzyme.  
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sequence, and bovine growth hormone Polyadenylation (bGH PA) as a specialized 
termination sequence for protein expression signal. 
This assembled CRISPR/Cas9 expression vector was verified by sequencing and 
was introduced into HCT116 cells by the PEI (Polyethylenimine) transfection protocol.  
Pools of transfected cells theoretically contain a mixture of wild type cells, cells with 
one mutated allele (heterozygous mutants) and cells that are mutated in both alleles 
(carrying either the same mutation on both alleles or two independent mutations on each 
allele). 
We designed the CRISPR/Cas9 system to target the last exon of the Tp53 gene 
(Figure 4.4).  The CRISPR/Cas9 enzyme is formed by the recruitment of the Cas9 
endonuclease to the target site by the fused scaffold-guide RNAs.  Recognition of the 
target site results in a DNA double strand break (DSB) (Figure 4.6).  DNA DSBs are 
fixed efficiently in mammalian cells by either non-homologous end joining (NHEJ) or 
by homologous recombination.  We assessed the formation of NHEJ mediated 
insertions and deletions (INDELs) by the restriction fragment length polymorphism 
assay conducted on PCR amplicons from genomic DNA isolated from cells that express 
CRISPR/Cas9.  To enrich the population of cells that express the CRISPR/Cas9 
endonuclease, we transiently selected the transfected cell pool with the antibiotic, 
puromycin, making use of the puromycin resistance gene in the pSpCas9(BB)-puro 
plasmid (Figure 4.6).  To ensure that off target DSB and INDEL generation is kept to a 
minimum, we performed puromycin selection only for 72 hours, relieving the selection 
to ensure that the CRISPR/Cas9 expressing plasmid is lost from the majority of dividing 
cells after several rounds of cell division. 
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Figure	  6	  
Figure 4.4: Annotation of primers used for RFLP and CRISPR target sites. The coding 
sequence of the last exon of the Tp53 gene is shown in yellow; the translation product 
of this exon is shown in single letter amino acid code on the bottom.  Forward and 
reverse primers used for RFLP analysis are annotated in light red (Long-FWD-primer 
and Long-REV-primer); mut#4, mut#5, and mut#9 deleted sequences (explained in 
detail later) are shown in light green and CRISPR/Cas9 target region is shown in dark 
green. The FauI restriction site used for RFLP is annotated in red.	  
 
	  
Figure	  7	  
Figure 4.5: Annealing of DNA oligonucleotides for cloning into guide RNA expression 
plasmids. 
 
Plasmid 48139: 
 pSpCas9(BB)-2A-Puro (PX459) 
For double strand break 
Plasmid 48141: 
 pSpCas9n(BB)-2A-Puro (PX462) 
For double nicking 
Figure. : pSpCas9(BB)Puro and pSpCas9n(BB)Puro plasmids are used 
to clone annealed oligos to create site-specific CRISPR/Cas9 or Cas9n 
plasmids for transfection.   Anne
aled' oligos Top' strand Bottom
'
strand
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Figure	  8	  
Figure 4.6: Experimental design of genome editing using the CRISPR/Cas9 system.  At 
the top, a segment of the Tp53 gene is shown that contains a partial exon 10, exon 11 
and the intervening intron 10.  The protein-coding region is shown in a purple box. A 
chosen CRISPR/Cas9 target sequence in this exon is indicated with 20 nt of yellow 
lettering, followed by the NGG PAM sequence,.  Oligonucleotides corresponding to this 
guide sequence were cloned into the pSpCas9(BB)-2A-Puro plasmid.  HCT116 cells 
were transfected with the pSpCas9(BB)-2A-Puro plasmid to generate mutations in the 
p53 CTD.  The potential outcomes of Tp53 gene targeting are shown in the bottom 
where cells could have mutations in one or both alleles, or remain wild type. 
 
 
 
 
Target'sequence'on'Tp53'gene’s'last'exon'
U6#
CBh#
3X#FLAG#
NLS#
SpCas9#
2A#
Puro#
NLS#
bGH#pA#
pSpCas9(BB)<2A<Puro#
Tra
ns
fec
Bo
n#
Wild#type#
#cells#
Heterozygous#
mutants#
Homozygous#
mutants#
3’- CGGGCGGTATTTTTTGAGTACCAAA -5’'5’- CACCGCCCGCCATAAAAAACTCATG -3’'
Cloning#into#BbsI#site#CCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGA …ccctctcactcatg…tctcctacag CA… 
GGTGGACTTCAGGTTTTTCCCAGTCAGATGGAGGGCGGTATTTTTTGAGTACAAGTTCTGTCTTCCCGGACTGAGTCTGACT GT… …gggagagtgagtac…agaggatgtc 
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Figure	  9	  
Figure 4.7: The mechanism of CRISPR/Cas9 interaction with DNA.  Cas9, an RNA-
directed DNA endonuclease, is recruited to the target of interest at the upstream of the 
PAM sequence with the help of single guide RNA (sgRNA).  Cas9 introduces DNA 
double strand breaks in the Tp53 gene, exactly 3 nt upstream of the PAM sequence.  
This break is repaired either by non-homologous end joining (NHEJ) in which a random 
mutation appears (shown on the left), or by homologous recombination, if a donor DNA 
is co-transfected into the cells to act as a template for DNA repair (shown on the right). 
 
As done for TALEN transfected cells, RFLP analysis was conducted for 
CRISPR/Cas9 and CRISPR/Cas9n systems; CRISPR/Cas9n has a mutated Cas9 
enzyme that could only introduce a nick to the strand it binds to, therefore two Cas9n 
proteins bind to top and bottom strands separately to create a DSB, similar to TALEN 
proteins.  Following transfecting cells with CRISPR/Cas9 and Cas9n plasmids, we 
could confirm that a mutated population exists in our transfected pool, which was 
represented by a faint uncut band in the RFLP analysis.  We cloned the undigested 
bands into a plasmid (PTZ57R/T in this case), transformed these plasmids into E.coli 
and sequenced the inserted DNA from several colonies derived from the transformed 
bacteria.  At the same time, we performed single cell cloning by limiting dilution assays 
in 96-well plates. 
CCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAACTCATGTTCAAGACAGAAGGGCCTGACTCAGACTGA 
GGTGGACTTCAGGTTTTTCCCAGTCAGATGGAGGGCGGTATTTTTTGAGTACAAGTTCTGTCTTCCCGGACTGAGTCTGACT 
Recogni(on)
)lobe)
Nuclease)lobe)
sgRNA)
Donor%DNA% Homologous%%
recombina3on%
NHEJ%
Desired%muta3on%Random%muta3on%
3’ 
5’ 
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4.2.  Homology Directed CTMs 
 
 
Our first trial in creating CTM cell lines, was to make a homology directed 
mutation in HEK293 cell lines.  We co-transfected a donor-DNA that contained two 
homology arms, a restriction site for RFLP screening (that does not present in the wild 
type sequence), and Lysine to Alanine codon change (Figure 4.8). 
HEK293 cells were transfected and RFLP experiment was conducted to check 
the efficiency of homology directed repair (HDR).  HDR efficiency is not high as 
expected.  Nevertheless, transfected pool was diluted to screen for K381A single cell 
clones.  RFLP results showed that one clone seems to have the desired mutation (HR3 
clone).  Sequencing results confirmed the K381A mutation in HR3 clone.  HR3 CTM 
cell line could accumulate p53 as efficient as WT cells (Figure 4.9).  Our studies on this 
mutant are ongoing in a separate project.  We moved on with p53 CTD characterization 
with other CTM cell lines that we obtained through NHEJ-induced random mutants. 
 
        	  
Figure	  10	  
Figure 4.8: Design of the donor DNA for homology-directed mutation of HEK293 cells. 
Single-stranded oligonucleotides (ss-oligo) were designed to mutate the K381 amino 
acid of p53 protein to Alanine. This ss-oligo introduces a HindIII restriction site which 
generates a silent mutation that was designed to detect HDR(+) clones by RFLP.  Silent 
mutations were designed by considering the abundance of the chosen codon in human 
cells. 
 
Figure. : Homology directed mutation in HEK293 cells. a) ss-oligo is designed to mutate K381 to Alanine and a HindIII restriction site is 
introduced using silent mutation to enable us to detect HDR(+) clones with RFLP. b) RFLP was applied to see if CRSIPR has örke efficiently; 
although uncut band is detectable in the pool showing a population of mutated cells, HindIII digestion is not detectable in the pool (very low HDR 
efficiency). Nevertheless, single cell clones are screened to find a homozygous K382A cells. c) HEK293 single cell clones screening after 
transfection; on the left, PCR products are shown. In the middle both WT cells and HR3 mutant are cut with FauI (showing that the restriction site 
is intact). HindIII cannot cut PCR products of the WT cells, since there is no HindIII site in that region originally, but PCR product of HR3 is cut, 
showing that HDR is successful. d) Mutation is confirmed by sequencing. e) No change in p53 accumulation after Doxorubicin treatment is 
detected for HR3 cells. 
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Figure	  11 
                       
 
Figure 4.9: Homology directed mutagenesis using the CRISPR/Cas9 system with ss-
oligonucleotides.  a) CRSIPR efficiency was assessed by RFLP; an uncut band is 
detectable in the pool indicating the presence of a population of mutated cells. HindIII 
digestion is not detectable in the pool of CRISPR/Cas9, indicating a very low HDR 
efficiency.  We could not detect any bands from CRISPR/Cas9n transfected cells 
because with donor DNA co-transfection was only performed with CRISPR/Cas9.  
Figure. : Homology directed mutation in HEK293 cells. a) ss-oligo is designed to mutate K381 to Alanine and a HindIII restriction site is 
introduced using silent mutation to enable us to detect HDR(+) clones with RFLP. b) RFLP was applied to see if CRSIPR has örke efficiently; 
although uncut band is detectable in the pool showing a population of mutated cells, HindIII digestion is not detectable in the pool (very low HDR 
efficiency). Nevertheless, single cell clones are screened to find a homozygous K382A cells. c) HEK293 single cell clones screening after 
transfection; on the left, PCR products are shown. In the middle both WT cells and HR3 mutant are cut with FauI (showing that the restriction site 
is intact). HindIII cannot cut PCR products of the WT cells, since there is no HindIII site in that region originally, but PCR product of HR3 is cut, 
showing that HDR is successful. d) Mutation is confirmed by sequencing. e) No change in p53 accumulation after Doxorubicin treatment is 
detected for HR3 cells. 
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Figure. : Homology directed mutation in HEK293 cells. a) ss-oligo is designed to mutate K381 to Alanine and a HindIII restriction site is 
introduced using silent mutation to enable us to detect HDR(+) clones with RFLP. b) RFLP was applied to see if CRSIPR has örke efficiently; 
although uncut band is detectable in the pool showing a population of mutated cells, HindIII digestion is not detectable in the pool (very low HDR 
efficiency). Nevertheless, single cell clones are screened to find a homozygous K382A cells. c) HEK293 single cell clones screening after 
transfection; on the left, PCR products are shown. In the middle both WT cells and HR3 mutant are cut with FauI (showing that the restriction site 
is intact). HindIII cannot cut PCR products of the WT cells, since there is no HindIII site in that region originally, but PCR product of HR3 is cut, 
showing that HDR is successful. d) Mutation is confirmed by sequencing. e) No change in p53 accumulation after Doxorubicin treatment is 
detected for HR3 cells. 
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transfection; on the left, PCR products are shown. In the middle both WT cells and HR3 mutant are cut with FauI (showing that the restriction site 
is intact). HindIII cannot cut PCR products of the WT cells, since there is no HindIII site in that region originally, but PCR product of HR3 is cut, 
showing that HDR is successful. d) Mutation is confirmed by sequencing. e) No change in p53 accumulation after Doxorubicin treatment is 
detected for HR3 cells. 
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Single cell clones from CRISPR/Cas9 transfected pools were screened to find 
homozygous K382A mutant cells.  b) HEK293 single cell clone screening after 
transfection. PCR products (left panel) were digested with FauI (middle panel) 
indicating that the restriction site is intact.  HindIII (right panel) cannot cut PCR 
products from WT cells, because there is no HindIII site in that region originally, but 
PCR products from HR3 are cut, indicating that HDR was successful.  c) The presence 
of a mutation was confirmed by sequencing.  WT sequence (top panel) and HR3 mutant 
(bottom panel) differ in the indicated positions identified by the Blast program d) No 
change in p53 accumulation after Doxorubicin treatment is detected for HR3 cells 
before and after Doxorubicin treatment.  p53 western blot at the top and Actin loading 
control at the bottom is shown. 
 
 
4.3.  NHEJ Mediated CTM: mut#4, mut#5, and mut#9 
 
 
The main focus of this study is three cell lines that we obtained from NHEJ 
repair mechanism after transfecting HCT116WT cells with CRISPR/Cas9 system.  
These homozygous mutants were detected after several single cell clone screening: 
mut#4, mut#5 and mut#9.  mut#4 had 29 nucleotides deletion, 89 nucleotides were 
deleted in mut#5, and mut#9 lacked 3 nucleotides.  These three mutants were first 
detected with RFLP, and then sequenced to confirm their homozygousity and deleted 
region (Figure 4.11 and 4.12). 
Sequencing results were confirmed in more than 25 different clones to make 
sure of the same mutation in both alleles.  The mRNA sequence of the mutated region 
after the transcription, and also estimated protein sequence is shown in schematic 
figures for wild type and CTM cells (Figure 4.13). 
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Figure	  12 
 
    
 
Figure 4.10: Non-Homologous End Joining (NHEJ) mediated random mutations using 
the CRISPR/Cas9 system.  a) HCT116 human colon cancer cells were transfected with 
CRISPR/Cas9 and CRISPR/Cas9n plasmids.  RFLP analysis was performed on 
transfected pools.  The third lane on the left shows a faint band (in the white rectangle), 
which represents the PCR product from the mutated cells that do not have a FauI site.  
b) The uncut bands were sequenced to identify various mutations in the pool of 
transfected cells.  CRISPR/Cas9 mutation is shown at the top, and CRISPR/Cas9n at the 
bottom.  Insertions are shown in green and the CRISPR binding site is highlighted. 
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Figure. : Electrophoresis gel figure of RFLP 
experiment of CRISPR/Cas9 and CRISPR/
Cas9n transfecetd cells; a) HCT116WT cells are 
transfected with CRISPR/Cas9 and CRISPR/
Cas9n plasmids. DNA of the transfecetd pool is 
extracted and the target region is amplified by 
PCR (on the right); the transfecetd pool is 
digested with FauI restriction site (shown on the 
left). DNA ladder is shown in the middle of the 
gel. RFLP (restriction fragment length 
polymorphism) method is used to figure out if 
the FauI site is intact or is destroyed due to 
CRISPR/Cas9 activity. The 3rd line on the left 
shows a faint band (in the white rectangle) 
which represents the PCR product from the 
mutated cells that do not have FauI site. b) The 
faint un-cut bands are sequenced to see various 
mutations in the pool of transfected cells. On the 
left, random mutations created by CRISPR/Cas9 
system is shown. On the right, several different 
deletions in CRISPR/Cas9n system are 
presented. 
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Figure. : Single cell clone screening. a) several single cell clones are  
screened by RFLP to find mutant clones; here several WT and one (colony 
no 8) heterozygous mutants are shown. b) Colony no 8 is diluted for the 2nd 
time to figure out if the clone is heterozygous, or is actually coming from 2 
clones, one WT, other one mutant; three heterozygous mutants are shown 
after an RFLP screening of clone no 8. PCR product from the WT allele of 
clone no 8 gets cut, but other mutant allele cannot be cut with the enzyme.  
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Figure	  13 
Figure 4.11: Single cell clone screening of CTM cell lines a) Single cell clone homozygous (#4 
and #9) and heterozygous (#10) mutants’ RFLP experiment after CRISPR/Cas9 transfection; 
from the left to the right, HCT116WT cells PCR amplicon (~300 nt) is cut into two fragments 
(~270 nt and 30 nt); mut#4 PCR amplicon is shorter than the WT and it cannot get cut (there are 
not FauI sites in any of the two alleles); mut#9 is not digested by FauI either; colony #10 is 
obviously mutated in one allele (there is an uncut band) and WT in the other allele (half of the 
PCR product is cut) b) RFLP analysis for several single cell clones show various mutations.  
Here, clone #5 is not amplified with our primes, which is due to a big mutation (89 nt) that 
includes our forward primer’s binding site.  We confirmed the exact deletion by selecting other 
primers with longer amlicons.  c) Again, various mutations in which colony#13 looks 
homozygous (which was later confirmed to have R379 deletion, just like mut#9) and colony#11 
has the exact mutation as mut#5 (89 nt deletion). 
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Figure  : Single cell clone homozygous (#4 and #9) and heterozygous (#10) mutants’ RFLP 
experiment after CRISPR/Cas9 transfection; from the left to the right, HCT116WT cells PCR 
amplicon (~300 nt) is cut into two fragments (~250 nt and 50 nt); mut#4 PCR amplicon is 
shorter than the WT and it cannot be cut (there are not FauI sites in none of the two alleles); 
mut#9 is not digested by FauI either; mut#10 is obviously mutated in one allele (there is a 
uncut band) and WT in the other allele (half of the PCR product is cut into two smaller 
bands)  
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Figure	  14 
 
Figure 4.12: Sequencing analysis of mut#4, mut#5, and mut#9.  a) Un-transfected cells 
sequencing results..  The coding sequence of the last exon of the Tp53 gene is shown in 
yellow.  The CRISPR binding site is also shown in gray and the FauI enzyme restriction 
site is illustrated in red.  b) 29 nt mutation both alleles of mut#4 is confirmed by 
sequencing several clones.  c) 89 nt deletion in mut#5 starts from 10-11 intron and 
continues to the last exon.  d) 3 nt deletion in mut#9 which follows R379 deleted p53 
protein for these cell lines.  e) All three mutations are illustrated on the Tp53 gene’s last 
exon as green arrows.  
  
e)	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Figure	  15 
1" 2" 3" 4" 5" 6" 7" 8" 9" 11"10"
CCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAAC…TGA"""CATTC…"gtgagtg….ccctctcactcatgtgatgtcatctctcctccctgc6ctgtctcctacag"
CCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAAC…TGA"""CATTC…"gtgagtg….ccctctcactcatgtgatgtcatctctcctccctgc6ctgtctcctacag"
…"S"""S"""H"""L"""K"""S"""K"""K"""G"""Q"""S"""T"""S"""R"""H"""K"""K"""L"""M"""F"""K"""T"""E"""G"""P""D"""S"""D""BB""
…UCCAG"gugagug….cccucucacucaugugaugucaucucuccucccugcuucugucuccuacag"CCACCUGAAGUCCAAAAAGGGUCAGUCUACCUCCCGCCAUAAAAAACU…UGA""CAUUC…"
…UCCAGCCACCUGAAGUCCAAAAAGGGUCAGUCUACCUCCCGCCAUAAAAAACUCAUGUUCAAGACAGAAGGGCCUGACUCAGACUGA"
…TCCAG"
…"S"""S"""H"""L"""K"""S"""K"""T"""H"""V"""Q"""D"""R"""R"""A""BB""
…UCCAG"gugagug….cccucucacucaugugaugucaucucuccucccugcuucugucuccuacag"CCACCUGAAGUCCAAAACU…UGA""CAUUC…"
…UCCAGCCACCUGAAGUCCAAAACUCAUGUUCAAGACAGAAGGGCCUGACUCAGACUGA"
29 bp deletion 
…TCCAG"
Splicing"
Acceptor"Site"PolyBpyrimidine"Tract"
Splicing"
Donor"Site"
1" 2" 3" 4" 5" 6" 7" 8" 9" 11"10"
CCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAAC…TGA"""CATTC…"gtgagtg….ccctctcactcatgtgatgtcatctctcctccctgc6ctgtctcctacag"
CCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAAC…TGA"""CATTC…"gtgagtg….ccctctcactcatgtgatgtcatctctcctccctgc6ctgtctcctacag"
…"S"""S"""H"""L"""K"""S"""K"""K"""G"""Q"""S"""T"""S"""R"""H"""K"""K"""L"""M"""F"""K"""T"""E"""G"""P""D"""S"""D""BB""
…UCCAG"gugagug….cccucucacucaugugaugucaucucuccucccugcuucugucuccuacag"CCACCUGAAGUCCAAAAAGGGUCAGUCUACCUCCCGCCAUAAAAAACU…UGA""CAUUC…"
…UCCAGCCACCUGAAGUCCAAAAAGGGUCAGUCUACCUCCCGCCAUAAAAAACUCAUGUUCAAGACAGAAGGGCCUGACUCAGACUGA"
…TCCAG"
…"S"""S"""H"""L"""K"""S"""K"""T"""H"""V"""Q"""D"""R"""R"""A""BB""
…UCCAG"gugagug….cccucucacucaugugaugucaucucuccucccugcuucugucuccuacag"CCACCUGAAGUCCAAAACU…UGA""CAUUC…"
…UCCAGCCACCUGAAGUCCAAAACUCAUGUUCAAGACAGAAGGGCCUGACUCAGACUGA"
29 bp deletion 
…TCCAG"
Splicing"
Acceptor"Site"PolyBpyrimidine"Tract"
Splicing"
Donor"Site"
1" 2" 3" 4" 5" 6" 7" 8" 9" 11"10"
CCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAAC…TGA"""CATTC…"gtgagtg….ccctctcactcatgtgatgtcatctctcctccctgc6ctgtctcctacag"
CCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAAC…TGA"""CATTC…"gtgagtg….ccctctcactcatgtgatgtcatctctcctccctgc6ctgtctcctacag"
…"S"""S"""H"""L"""K"""S"""K"""K"""G"""Q"""S"""T"""S"""R"""H"""K"""K"""L"""M"""F"""K"""T"""E"""G"""P""D"""S"""D""BB""
…UCCAG"gugagug….cccucucacucaugugaugucaucucuccucccugcuucugucuccuacag"CCACCUGAAGUCCAAAAAGGGUCAGUCUACCUCCCGCCAUAAAAAACU…UGA""CAUUC…"
…UCCAGCCACCUGAAGUCCAAAAAGGGUCAGUCUACCUCCCGCCAUAAAAAACUCAUGUUCAAGACAGAAGGGCCUGACUCAGACUGA"
…"S"""R""BB""
…UCCAG"guga""ACU…GA"""CAUUC…"
…UCCAGguga"
89 bp deletion 
…TCCAG"
…TCCAG"
1" 2" 3" 4" 5" 6" 7" 8" 9" 11"10"
CCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAAC…TGA"""CATTC…"gtgagtg….ccctctcactcatgtgatgtcatctctcctccctgc6ctgtctcctacag"
CCACCTGAAGTCCAAAAAGGGTCAGTCTACCTCCCGCCATAAAAAAC…TGA"""CATTC…"gtgagtg….ccctctcactcatgtgatgtcatctctcctccctgc6ctgtctcctacag"
…"S"""S"""H"""L"""K"""S"""K"""K"""G"""Q"""S"""T"""S"""R"""H"""K"""K"""L"""M"""F"""K"""T"""E"""G"""P""D"""S"""D""BB""
…UCCAG"gugagug….cccucucacucaugugaugucaucucuccucccugcuucugucuccuacag"CCACCUGAAGUCCAAAAAGGGUCAGUCUACCUCCCGCCAUAAAAAACU…UGA""CAUUC…"
…UCCAGCCACCUGAAGUCCAAAAAGGGUCAGUCUACCUCCCGCCAUAAAAAACUCAUGUUCAAGACAGAAGGGCCUGACUCAGACUGA"
…"S"""S"""H"""L"""K"""S"""K"""K"""G"""Q"""S"""T"""S"""H"""K"""K"""L"""M"""F"""K"""T"""E"""G"""P""D"""S"""D""BB""
…UCCAG"gugagug….cccucucacucaugugaugucaucucuccucccugcuucugucuccuacag"CCACCUGAAGUCCAAAAAGGGUCAGUCUACCUCCCAUAAAAAACU…UGA"""CAUUC…"
…UCCAGCCACCUGAAGUCCAAAAAGGGUCAGUCUACCUCCCAUAAAAAACUCAUGUUCAAGACAGAAGGGCCUGACUCAGACUGA"
3 bp deletion 
…TCCAG"
…TCCAG"
a)	  
c)	  
b)	  
d)	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Figure 4.13: Predicted p53 gene DNA, RNA, and Protein structure of mut#4, mut#5, 
and mut#9.  a) At the top, the Tp53 gene is shown with its 11 exons.  3’ un-translated 
region (UTR) and 5’ UTR are shown in pink boxes.  Coding region is shown in the 
purple box, and introns are the brown lines in between the exons.  The end of the 10th 
exon, intron 10-11, and the last exon (11th exon) of the Tp53 gene is magnified for wild 
type p53 and mut#4.  Right under the illustration of the Tp53 gene, a precursor RNA is 
shown in the light green box.  Sequences transcribed from exons, are shown in pink 
letters and sequences transcribed from introns are shown in purple letters.  Mature 
mRNA is displayed in dark green box; here splicing occurs and introns are removed 
from the pre-mRNA.  The next step is translation; protein sequence is written in the 
dark purple box below the mature mRNA.  The amino acids coming from the three-
letter mRNA codes are shown.  b) mut#4 has truncated p53 due to 29 nt deletion.  It 
also has a non-WT tail coming from the frame-shift as well.  The deleted part of the 
genome is removed from the precursor RNA as well as the mature mRNA.  29 nt 
deletion leads to frame-shift in the translation and a shorter non-WT tail is the 
consequence of this mutation.  c) mut#5 completely lacks the last exon because of 89 nt 
deletion, starting from intron 10-11, that makes splicing between exon 10 and 11 
impossible (polypyrimidine tract and also acceptor site of the intron is deleted which 
theoretically makes splicing impossible); therefore it most probably loses the last exon 
completely in the protein.  d) mut#9 lacks one amino acid (R379) as the consequence of 
3 nucleotide deletion.  This deletion is shown in orange letters in the DNA sequence of 
the last exon.  These three nucleotides are removed from the mRNA sequences, and the 
protein sequence of the mut#9 lacks R379 accordingly. 
 
Fig 
4.3.1.  Phenotypic Specificities of the CTM Cell Lines 
 
Different aspects Our CTM cell lines were investigated, trying to identify 
phenotypes specific to a mutant.  We checked protein expression for several genes 
including p53, p21, PUMA, and MDM2.  We also checked if p53 in CTM cell lines 
could bind to its DNA target as efficient as the wild type p53.  Since p53 is a 
transcription factor, we looked at mRNA amount of a number of the p53 protein target 
genes in HCT116 human colon cancer cell lines with/without wild type p53, and 
compare them with the mRNA amount of the same group of genes in our CTM cell 
lines.  During our studies, we found that some of the CTM cell lines grow slower than 
the HCT116 cells with wild type p53; we confirmed this cell doubling-time difference 
experimentally. 
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4.3.2.  The p53 Protein Expression in CTM Cell Lines 	  
Western blot experiment was conducted to compare the expression pattern of the 
p53 protein and some of its target genes (p21, PUMA, and MDM2).  To induce p53 
expression in our cells, we exposed them to various genotoxic stresses such as 
Doxorubicin (1 µM), Cisplatin (100 uM), or Nutlin (10 uM) treatments.  In figure 4.14, 
western blot experiment of HCT116WT and all CTMs is shown.  WT cells mut#4, and 
mut#9 could accumulate p53 after Doxorubicin treatment, but mut#5 seems to have 
serious accumulation problems.  p53 in mut#5 could be detected as a faint band in 
cytoplasm lysate though.  p53 accumulation after Doxorubicin treatment is 
approximately the same for HCT115WT cells and mut#4 and mut#9 CTM cell lines.  
Shorter p53 protein is clearly presented in p53 western blot.  After Doxorubicin 
treatment and also serum starvation (serum starvation stress is induced by keeping cells 
in EBSS medium (Biological Industries®) for 16 h), mut#9 p21 expression is 
significantly less than mut#4 and WT cells.  PUMA expression in un-treated cells and 
cells under stress is very similar (Figure 4.15).  Unlike other p53 CTM cell lines, mut#5 
cannot accumulate p53 properly under stress.  We compared p53 accumulation in 
mut#5 and mut#9 in different conditions such as un-treated, Nutlin treated (10 µM 16h), 
Doxorubicin treated (1 µM 24h), and Cisplatin treated (100 µM 16h).  In each case, p53 
could not accumulate as much as mut#9 or wild type cells (Figure 4.16).  p53 
expression comparison between HCT116WT, HCT116KO, and mut#5 in western blot 
experiment was done as well which confirmed our previous findings (Figure 4.17). 
                    	  
Figure	  16	  
Figure 4.14: Analysis of p53 protein expression in HCT116WT and CTM cells by 
western blotting.  WT cells and mut#4 accumulate p53 after Doxorubicin treatment, but 
mut#9 accumulates less and mut#5 almost cannot accumulate p53.  p53 in mut#5 seems 
Figure. : Protein expression of p53, p21, and PUMA shown in 
western blot experiment. a) p53 accumulates after 
Doxorubicin treatment in HCT116WT, mut#4, and mut#9; the 
amount of the p53 protein is more or less the same in 
HCT116WT, mut#4, and mut#9; b) p21 is expressed less 
under genotoxic stress (Doxorubicin treatment) and also 
serum starvation compared to HCT116WT; c) PUMA 
expression does not change in between three cell lines under 
either of the stress conditions; d) actin western blot shows 
equal loading amount of cell lysates; e) Pull down experiment 
is performed by Biotinylated DNA probes (derived from the 
GADD45 promoter); mut#9 cannot bind to this DNA probe 
efficiently, GADD45 interacts with p21.   
Figure. : Western blot experiment of HCT116WT and all CTM mutants. WT cells and mut#4 accumulate 
p53 after Doxorubicin treatment, but mut#9 and more severely mut#5 cannot accumulate p53 as much. 
p53 in mut#5 seems to have translocation problem to the nucleus following DDR (DNA damage 
response) as it is present as a faint band in cytoplasm lysate but not nuclear lysate. Actin control is shown 
under the p53 western blot as well. 
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to have translocation problem to the nucleus following DDR (DNA damage response) 
as it is present as a faint band in cytoplasm lysate but not nuclear lysate.  Actin control 
is shown under the p53 western blot as well. 
 
	  
Figure	  17	  
Figure 4.15: Analysis of p53, p21, PUMA protein expression in mut#4 and mut#9, under 
normal condition (un-treated), after Doxorubicin treatment (1 µM for 24 h), and under 
serum starvation stress.  p53 accumulation after Doxorubicin treatment is approximately 
the same for HCT116WT cells and CTMs.  Shorter p53 protein is clearly presented in 
p53 blot.  For p21 protein expression, after Doxorubicin treatment and also serum 
starvation, mut#9 p21 expression is significantly less than mut#4 and WT cells.  PUMA 
expression in un-treated cells and cells under stress is very similar.  The amount of 
loaded protein for each sample is equal as it is shown in Actin western blot. 
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Figure	  18 
WT mut#5 mut#9 WT mut#5 mut#9 Un-­‐treated Nutlin 
Cytoplasmic	  lysate a) 
WT mut#5 mut#9 WT mut#5 mut#9 Doxorubicin Cisplatin 
Cytoplasmic	  lysate b) 
WT mut#5 mut#9 WT mut#5 mut#9 Un-­‐treated Nutlin 
Nuclear	  lysate c) 
WT mut#5 mut#9 WT mut#5 mut#9 
Doxorubicin Cisplatin 
Nuclear	  lysate d) 
e) WT mut#5 mut#9 WT mut#5 mut#9 Un-­‐treated Nutlin 
f) WT mut#5 mut#9 WT mut#5 mut#9 Doxorubicin Cisplatin 
	   59	  
Figure 4.16: Analysis of p53 protein expression in WT, mut#9, and mut#5 under 
different types of  genotoxic stress.  a) The p53 protein amount is compared in WT, 
mut#5, and mut#9 cells under normal condition and also Nutlin treated; in cytoplasm, 
p53 is accumulated in three cell lines, but less in mut#5 (shown with red arrow); b) 
Doxorubicin and Cisplatin induces DNA double strand break and p53 is accumulated 
following both treatments.  Again mut#5 accumulates less p53 in comparison.  c) Un-
treated and Nutlin treated WT, mut#5 and mut#9 p53 expression in the nuclei.  d) 
Doxorubicin and Cisplatin treated WT, mut#5, and mut#9; mut#5 seems not to be able 
to translocate into the nucleus, specially after Doxorubicin treatment.  Although there is 
no nuclear export region in the last exon of the p53, still the absence of this part seems 
to create translocation problems.  e) Actin control, showing that equal amounts of 
protein is loaded to each of the wells for un-treated and Nutlin treated samples.  f) Actin 
control, showing that equal amount of protein is loaded to each of the wells for 
Doxorubicin and Cisplatin treated samples. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure	  19	  
Figure 4.17: Analysis of  p53 expression in WT, KO, and mut#5.  a) Basal p53 
expression for WT cells is more than mut#5.  No p53 expression for HCT116KO.  p53 
accumulation is also less in mut#5 after Doxorubicin treatment.  b) p53 accumulation is 
more obvious in the cytoplasm for mut#5 cells.  c) Loading control; actin western blot 
shows the equal amounts of the loaded protein for each of the samples. 	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4.3.3.  DNA-Binding Activity of p53 in CTM Cell Lines 
 
To check whether p53 protein DNA binding activity is affected in the mutant 
cells or not, a pull-down experiment was conducted with DNA probes obtained from 
one of the p53 protein’s transcription targets (GADD45 promoter).  p53 of mut#9 binds 
less efficiently to its DNA target whereas mut#4 DNA binding efficiency is similar to 
the wild type cells (Figure 4.18). 
	   	  
Figure	  20	  
Figure 4.18: p53 protein expressed by mut#9 cells binds less efficiently to target DNA 
(p=0.0069).  a) Here pull down experiment results show that the transcriptional activity 
of mut#9 drops compared to HCT116WT and also mut#4.  b) Normalized p53 binding 
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activity is shown for three independent pull down experiments and compared in a 
graph; mut#9 binds less efficiently to its target DNA (p=0.0069). 
 
 
4.3.4.  p53 Translocation into the Nucleus in CTM Cell Lines 
 
Another interesting observation was that p53 could not translocate into the 
nucleus under stress, unlike what happens in wild type cells (Figure 4.16).  After several 
western blot experiments, we could almost conclude that mut#5 p53 cannot translocate 
efficiently into the nucleus after accumulation in the cytoplasm (Figure 4.19). 
The p53 protein accumulation and translocation after Doxorubicin treatment was 
checked for HCT116WT and mut#5 under confocal microscopy as well.  The results 
confirmed what we showed in western blot experiments.  p53 cannot accumulate in the 
nucleus of the mut#5 cells after genotoxic stress, which is Cisplatin treatment in this 
case.  Basal p53 expression is lower in mut#5 than HCT116WT cells.  Another thing, 
which was clearly noticed under confocal microscopy, was disability of mut#5 in losing 
their volume (cell shrinking) as much as WT cells during apoptosis (Figure 4.20).  This 
finding is clearly confirmed in xCELLigence experiments as well (Figure 4.27-b). 
	  
Figure	  21	  
Figure 4.19: p53 nuclear translocation is inhibited in mut#5 cells under stress.  p53 
accumulation is calculated for three different stress conditions (Nutlin, Doxorubicin, 
and Cisplatin treated).  p53 band intensity in mut#5 is divided by the p53 band intensity 
in the WT cells; here, the ratio for cytoplasmic p53 is compared with the ratio for 
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nuclear p53 and the difference between these amounts is significant, showing that the 
p53 protein cannot translocate into the nucleus. 
 P > 0.05: non-specific, P ≤ 0.05: *, P ≤ 0.01: **, P ≤ 0.001: ***, ***P ≤ 0.0001: ***. 
 
	  
	  
Figure	  22 
Figure 4.20: Confocal microscopic analysis of WT and mut#5 cells with and without 
stress.  a) Confocal microscopy pictures of HCT116WT cells versus mut#5 showing 
p53 expression.  The p53 protein is shown in green (488 2ndary antibody) and nuclei 
are shown in blue (DAPI staining).  p53 is accumulated in the nuclei of HT116WT cells 
after treatment but no significant increase is detectable for mut#5 cells.  b) p53 protein 
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amount in more than 200 cells are calculated for HCT116WT and mut#5 in normal 
condition and under genotoxic stress (Cisplatin treated in this case).  Basal p53 amount 
is lower in mut#5 in comparison with WT cells, and it is not accumulated in the nuclei 
of mut#5 cells after Cisplatin treatment.   
 
 
4.3.5.  mRNA Amount for p53 and p53 Target Genes in CTM Cell Lines  
 
To check if mRNA amount of the p53, p21, MDM2, and PUMA proteins in 
CTM cell lines and the WT cells are different, QRT PCR experiment was conducted, 
normalized to GAPDH gene transcription.  The p53 target gene transcriptions are 
different in CTM cell lines; mRNA amount is significantly lower in p53 and all its 
target gene for mut#9 and mut#5 after Doxorubicin treatment.  PUMA, p21, and p53 
mRNA amounts are lower for mut#4 under stress.  p53, p21, and MDM2 basal mRNA 
amount is significantly different in mut#5.  Also, mut#9 has higher basal mRNA 
amount for MDM2 and PUMA genes (Figure 4.21). 
The QRT PCR results are analyzed in a different way to check the change in 
mRNA amount of the p53, p21, PUMA, and MDM2 proteins before and after 
Doxorubicin treatment by normalizing each sample to its own un-treated mRNA 
amount (Figure 4.22). 
To compare mRNA amount of p53 and its target genes, HCT116WT, 
HCT116KO, and mut#5 transcription patterns were compared separately.  HCT116KO 
and mut#5 mRNA pattern is very similar in normal conditions and under stress (Figure 
4.23). 
According to some recent studies on CTD of the p53 protein and its relation 
with the telomere length, we compared mRNA amount for four telomere genes since 
cells with truncated p53 C-terminus tend to have shorter Telomeres 148.  QRT PCR 
results showed different telomere gene transcription under normal conditions and after 
Doxorubicin treatment (Figure 4.23). 
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Figure	  23 
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Figure 4.21: Quantitative realtime PCR analysis of p53, p21, MDM2, PUMA mRNA 
expression from WT, mut#4, mut#5, mut#9 cells (all normalized to HCT116WT un-
treated).  a) p53 transcription drops in the CTM cell lines.  Even under normal 
conditions, p53 mRNA amount of the WT cells is more than mut#5.  b) MDM2 mRNA 
amount is higher in mut#5 and mut#9 under normal conditions, but they increase less 
than the WT cells after Doxorubicin treatment.  c) PUMA mRNA amount in mut#5 is 
higher compared with WT cells, but the transcription of this gene is not increased as 
much in mut#5 and mut#9.  d) p21 basal mRNA amount is lower in mut#5.  After 
Doxorubicin treatment, p21 transcription is not increased as much as WT. 
 
	  
Figure	  24	  
 
Figure 4.22: Quantitative realtime PCR analysis of p53, p21, MDM2, PUMA mRNA 
expression from WT, mut#4, mut#5, mut#9 cells (all normalized to their own un-
treated); transcription change in p53 and its target genes (p21, PUMA, MDM2) after 
Doxorubicin treatment (1 uM, 24h).  a) p53 transcription does not increase as much as 
WT in CTM cell lines after Doxorubicin treatment.  b) MDM2 mRNA amount shows 
the same pattern as p53 mRNA.  c) PUMA transcription induces less that WT cells in 
mut#5 and mut#9.  d) p21 mRNA amount increases not as much as WT in CTM cell 
lines. 
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Figure	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Figure 4.23: Quantitative realtime PCR analysis of p53, p21, MDM2, PUMA mRNA 
expression from HCT116WT, HCT116KO, and mut#5 under normal conditions (UT) 
vs.  24h 1µM Doxorubicin treatment (Dox).  mut#5 transcription pattern for these genes 
is very similar to HCT116KO.  The p53 protein in mut#5 lacks the last exon, but still its 
transcriptom resembles to HCT116KO that is p53 knock-out.  p53 basic transcription is 
also lower (5 fold) in mut#5 compared to WT, and it doesn’t increase as much under 
stress; the most robust difference is seen for p21.  MDM2 transcription does not 
increase for HCT116KO and mut#5 under stress; PUMA mRNA amount for mut#5 is 
twice as much as HCT116KO, but still many folds less than HCT116WT. 
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Figure. : CTM cell lines have differentially expressed Telomere genes. a) hTERT, the gene for catalytic subunit of Telomerase enzyme, is 
not differentially expressed in CTM. b) Terf1 encodes Telomere specific protein which is an inhibitor of Telomerase. The mRNA amount 
drops more significantly for CTM cell lines  after Doxorubicin treatment (p=0.0044 for mut#4 and p=0.0009 for mut#5); c) Dkc1 is a 
member of Shelterin protein complex that protect Telomere tails. mut#9  and mut#4 decrease is less than  HCT116WT after Doxorubicin 
treatment (p=0.0001). mRNA amount of Dkc1 gene in mut#9 is also less compared to WT cells. d) Rtel1 is the major determinant of the 
Telomere length; this gene’s transcription drops significantly after Doxorubicin treatment in WT and mutant cells. Nevertheless, mRNA 
amount of this gene in CTM mutants are significantly less than WT after Doxorubicin treatment (p= 0.0001) 
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Figure 4.24: CTM cell lines have differentially expressed telomere genes.  a) hTERT, 
the gene for catalytic subunit of the telomerase enzyme, is not differentially expressed 
in CTM cell lines.  b) Terf1 encodes telomere specific protein, which is an inhibitor of 
telomerase.  The mRNA amount drops more significantly for CTM cell lines after 
Doxorubicin treatment (p=0.0044 for mut#4 and p=0.0009 for mut#9).  c) Dkc1 is a 
member of Shelterin protein complex that protect telomere tails.  mut#9 and mut#4 
decrease is less than  HCT116WT after Doxorubicin treatment (p=0.0001).  mRNA 
amount of Dkc1 gene in mut#9 is also less compared to WT cells.  d) Rtel1 is the major 
determinant of the Telomere length; this gene’s transcription drops significantly after 
Doxorubicin treatment in WT and mutant cells.  mRNA amount of this gene in CTMs 
are significantly less than WT after Doxorubicin treatment (p= 0.0001). 
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Figure. : CTM cell lines have differentially expressed Telomere genes. a) TERT, the gene for atalytic subunit of Telomerase e , is 
not differentially expressed in CTM. b) Terf1 encodes Telomere specific protein which is an inhibito  of Tel m ras . Th  mRNA amount 
drops more significantly for CTM cell lines  after Doxorubicin treatment (p=0.0044 for mut#4 and p=0.0009 for mut#5); c) Dkc1 is a 
member of Shelterin protein complex that protect Telomere tails. mut#9  and mut#4 decrease is less than  HCT116WT after Doxorubicin 
treatment (p=0.0001). mRNA amount of Dkc1 gene in mut#9 is also less compared to WT cells. d) Rtel1 is the major determinant of the 
Telomere length; this gene’s transcription drops significantly after Doxorubicin treatment in WT and mutant cells. Nevertheless, mRNA 
amount of this gene in CTM mutants are significantly less than WT after Doxorubicin treatment (p= 0.0001) 
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4.3.6.  Cell Doubling Time Increase in CTM Cell Lines  
 
During routine splitting of our CTM cell lines, we recognized a lower growth 
rate for mut#9 and mut#5 compared to HCT116WT cells.  We experimentally 
confirmed this observation with xCELLigence experiment results, shown in Figure 
4.25-28. 
Although mut#5 and HCT116KO transcription pattern for p53, p21, PUMA, and 
MDM2 genes were very similar (Figure 4.23), but mut#5 cell doubling time is 
significantly longer than HCT116KO cells (Figure 4.26).  To compare mut#5 and 
mut#9 doubling times, another xCELLigence experiment was conducted.  We 
concluded that mut#5 grows slower than mut#9 and HCT116WT (Figure 4.27 and 
7.28). 
	  
Figure	  27	  
Figure 4.25: Doubling time analysis of HCT116WT cells in comparison with mut#4 and 
mut#9.  a) HCT116WT cells divide faster than mut#9.  b) The difference between 
doubling time of the three cell lines are shown; HCT116WT cells significantly (p= 
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0.0003) grow faster than mut#9.  The difference between cell doubling time of mut#4 
and HCT116WT is not significant (p= 0.02). 
 
 
	  
Figure	  28 
Figure 4.26: Growth rate comparison of HCT116WT and HCT116KO and mut#5 cells.  
a) mut#9 grows slower than HCT116WT and HCTKO, this can be an indicator of a 
mutant dominant effect of the p53 protein in mut#5.  b) A significant difference 
(p=0.0023) between cell doubling time in HCT116WT/HCT116KO and mut#5. 
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Figure 4.27: Analysis of doubling time in WT, mut#5, and mut#9 cells with or without 
stress.  a) Real-time cell growth is shown for HCT116WT, mut#5, and mut#9 under 
normal condition (growth phase and plateau) or under stressed condition (1 uM 
Doxorubicin 24h treatment); mut#5 and mut#9 b) mut#5 cell doubling time is 
significantly higher than wild type cells and they do not lose volume as much as WT 
cells during apoptosis. 
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Figure 4.28: mut#5 and mut#9 cells grow slower than HCT116WT cells.  Both CTM 
cell lines grow slower than HCT116WT.  The difference between HCT116WT and 
mut#5 is more significant (p= 0.01) than the difference between HCT116WT and mut#9 
(p= 0.04).   
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5.  DISCUSSION 
 
 
 
We demonstrated that p53 C-terminal is extremely crucial for the protein’s 
function by studying the behavior of p53 CTM cell lines in basal condition and under 
different types of cellular stress, such as treatment by Doxorubicin, Cisplatin, or Nutlin 
and serum starvation.  In this study, we investigated the different aspects of the p53 
tumor suppressor protein, its transcriptional targets and also proteins that regulate p53 
activation.  We studied endogenous p53 by creating homozygous mutants using 
CRISPR/Cas9 technology.  The focus of this study was three CTM cell lines that 
encode three different mutant types of p53 protein: 1) a truncated p53 protein (p53 Δ21 
/ Δ21) called mut#4; 2) a p53 protein missing the C-terminus encoded by the last p53 
exon (p53 Δ26 / Δ26) called mut#5, and 3) a single amino acid deleted p53 protein (p53 
ΔR379 / ΔR379) called mut#9.   
p53 Δ21 / Δ21: p53 Δ21 / Δ21 or as mentioned in the thesis, mut#4, did not 
show any differences in the accumulation of the p53, p21, and PUMA proteins in the 
stressed cells.  This CTM cell line could also bind to its DNA target as efficiently as the 
wild type cells.  Therefore we concluded that p53 truncation of this mutant, is not 
affecting p53 accumulation, tetramerization, and DNA binding efficiency.  The 
interesting point about this mutant was that unlike mut#5, which lacks the last 26 amino 
acids of its p53 protein, mut#4 had a non-wild type tail with the amino acid sequence (T 
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H V Q D R R A).  This change in C-terminal amino acid sequence arises from a frame 
shift mutation.  This tail could potentially behave similar to WT p53 protein by 
compensating for the important amino acid R379.  Even though, in total, mut#4 is 13 
amino acids shorter than the wild type p53 the presence of arginine amino acids in the 
last three positions may cause it to fold into a three dimensional shape and behave 
similar to WT p53.  mut#4 does not demonstrate a very different transcription pattern 
from wild type cells in comparison with other two CTM cell lines (mut#5 and mut#9).  
It can increase the transcription of MDM2 and PUMA efficiently after Doxorubicin 
treatment.  This shows the transcription factor activity of this mutant is not damaged as 
much as other CTM cell lines.  Here we could refer to a target-dependent manner in 
which CTD influences DNA binding efficiency to its different targets128,131.  As for 
mut#4, p21 (high affinity distal binding site) mRNA amount is affected whereas PUMA 
(medium affinity distal binding site) and more specifically MDM2 (closely-spaced low 
affinity binding site) mRNA levels are not changed as much.  This is consistent with the 
literature on the selective DNA anchoring ability of the CTD128.   
mut#4 also shows a different transcription pattern for some genes that play 
important roles in ribosome biogenesis stress.  As mentioned in the introduction, 
ribosomal protein RPL11 is important in the recruitment of p300/CBP, which leads to 
p53 K382 acetylation and activation19.  It is possible that the differentially transcribed 
ribosome biogenesis genes could partially be influenced by the absence of the K382 
residues in this mutant.   
p53 Δ26 / Δ26: p53 Δ26 / Δ26 totally lacks the last exon of the Tp53 gene.  This 
mutant, also called mut#5, displays a very different transcriptional pattern in 
comparison with wild type cells and also with our other CTM cell lines.  The most 
robust phenotype detected in this mutant was the low accumulation of the p53 protein in 
the nucleus after genotoxic stress.  The accumulation is almost undetectable in the 
nucleus, but not in the cytoplasm.  Although there is no nuclear localization signal 
encoded by the last exon of the Tp53 gene, the protein encoded by this mutant cannot 
translocate into the nucleus.  It could be discussed that since p53 CTD post-translational 
modification plays an important role in p53 function59, the deletion of the last exon that 
includes many PTM sites, influences p53 conformational change which in turn causes 
its translocation problem.  It is expected that the p53 in mut#5 cannot induce its target 
genes because not only the p53 is not accumulated efficiently, but also it cannot enter 
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the nucleus to play its transcription factor role; this was validated by QRT PCR results.  
Furthermore, apoptotic mut#5 cells do not go through nuclear shrinkage properly; we 
observed this phenotype in the xCELLigence and confocal microscopy results. 
In accordance to previous studies that proved the relationship between p53 CTD 
and telomere length, differentially transcribed genes Dkc1 and Rtel1 might be the main 
reason that mut#5 growths slower than HCT116WT148.  Another possibility is the effect 
of this deletion mutation on the Glycolysis pathway and consequently to the metabolism 
of the mutated cell.  This mutant cell line transcribes p53 and several other genes that 
play crucial role in cell cycle arrest and apoptosis, in lower amounts, regardless of stress 
conditions.  Furthermore, the transcription pattern of this mutant resembles HCT116KO 
that does not express p53 at all.  On the contrary, HCT116KO cell doubling time is the 
same as HCT116WT.  This contradiction could be explained by the presence of p47, 
which is a shorter isoform of p53 protein that is not detected in mut#5.  It is reported 
that p47 accumulates under stress and can fulfill some of p53 responsibilities, such as 
cell death149.  This truncated protein is negatively regulated by p53, and is normally 
suppressed by the accumulation of the p53 protein, in the cell lines in which p53 is not 
expressed (e.g. HCT116KO).  As a result p47 is expressed and accumulated possibly for 
the compensation of p53 protein.  It is arguable that the difference in the cell growth 
rate of mut#5 and HCT116KO, while their transcription pattern for p53, p21, MDM2, 
and PUMA is very similar, is due to the presence of p47 in HCT116KO cells. 
p53 ΔR379 / ΔR379: p53 ΔR379 / ΔR379 (mut#9) lacks one amino acid in its 
CTD.  It is unexpected to observe significant phenotypic differences in this mutant since 
it lacks only one amino acid, which is barely mentioned in the literature.  However, it is 
demonstrated that p53 in mut#9 cannot bind to its DNA target efficiently.  It is very 
intriguing that one amino acid, that wasn’t previously shown to play an important role 
in PTM in p53 studies, could make such an effect in the most important activity of the 
protein.  As a result of this deficiency, it is presumable that transcription of p53 target 
genes in mut#9 is significantly lower, as we confirmed in our QRT PCR results.  
Moreover, telomere gene mRNA amount drops in this mutant.  Additionally, we 
showed that mut#9 grows slower just like mut#5.  This founding is interesting since this 
increase in cell doubling time is apparent in mut#9 and mut#5 (both lack R379), but not 
in mut#4 (which theoretically has R379).  According to all these findings, it is possible 
to claim that R379 is extremely important in p53-dependant cell metabolism.  In order 
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to further explore this argument, we are currently conducting mass spectrophotometry 
experiments with our CTM cell lines to compare their PTM pattern with wild type cells.  
Then we would be able to reach a more certain conclusion. 
In conclusion, we showed how different mutations in the CTD of the p53 protein 
affect cells in various ways.  Our contribution to the literature was to identify R379 as a 
very critical amino acid in the C-terminus, that influences cellular metabolism.  We also 
demonstrated that the p53 CTD influences ribosome biogenesis by controlling the 
transcription of ribosomal protein genes (RNA-seq data).  Finally we identify the region 
of the p53 protein encoded by the last exon of the Tp53 gene as being critical for the 
activity, accumulation, and translocation of this protein. 
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APPENDIX 
 
 
 
 
APPENDIX A: Chemicals Used in the Study 
 
 
 
Chemicals and Media Components Supplier Company 
  2-Mercaptoethanol Sigma, Germany 
Acetic Acid Merck, Germany 
Acid Washed Glass Beads Sigma, Germany 
Acrylamide/Bis-acrylamide Sigma, Germany 
Agarose peQLab, Germany 
Ammonium Persulfate Sigma, Germany 
Ammonium Sulfate Sigma, Germany 
Ampicillin Sodium Salt CellGro, USA 
Bacto Agar BD, USA 
Bacto Tryptone BD, USA 
Boric Acid Molekula, UK 
Bradford Reagent Sigma, Germany 
Bromophenol Blue Sigma, Germany 
Chloramphenicol Gibco, USA 
D-Glucose Sigma, Germany 
Distilled water Milipore, France 
DMEM PAN, Germany 
DMSO Sigma, Germany 
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DNA Gel Loading Solution, 5X Quality Biological, Inc, USA 
DPBS CellGro, USA 
EDTA Applichem, Germany 
Ethanol Riedel-de Haen, Germany 
Ethidium Bromide Sigma, Germany 
Fetal Bovine Serum (FBS) Biological Industries, Israel 
Glycerol Anhydrous Applichem, Germany 
Glycine Applichem, Germany 
HBSS CellGro, USA 
HEPES Applichem, Germany 
Hydrochloric Acid Merck, Germany 
Isopropanol Riedel-de Haén, Germany 
Kanamycin Sulfate Gibco, USA 
LB Agar BD, USA 
LB Broth BD, USA 
L-Glutamine Hyclone, USA 
Liquid nitrogen Karbogaz, Turkey 
Magnesium Chloride Promega, USA 
Methanol Riedel-de Haen, Germany 
Monoclonal Anti-HA Antibody Sigma, Germany 
p53 Mouse Antibody Cell Signalling Technology, USA 
p53 Polyclonal Antibody Cell Signalling Technology, USA 
PATZ1 (H-300) Antibody Santa Cruz, USA 
Penicillin-Streptomycin Sigma, Germany 
Phenol-Chloroform-Isoamylalcohol Amersco, USA 
PIPES Sigma, Germany 
Potassium Acetate Merck, Germany 
Potassium Chloride Fluka, Germany 
Potassium Hydroxide Merck, Germany 
Protease Tablets (EDTA-free) Roche, Germany 
ProtG Sepharose Amersco, USA 
RNase A Roche, Germany 
RPMI 1640 PAN, Germany 
SDS Protein Gel Loading Pack Fermentas, Germany 
SDS Pure Applichem, Germany 
Skim Milk Powder Fluka, Germany 
Sodium Azide Amresco, USA 
Sodium Chloride Applichem, Germany 
SuperSignal Chemiluminescent Substrate Thermo Scientific, USA 
TEMED Applichem, Germany 
Tris Buffer Grade Amresco, USA 
Tris Hydrochloride Amresco, USA 
Triton X100 Promega, USA 
Tween20 Sigma, Germany 
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APPENDIX B: Equipment Used in the Study 
 
 
 
Equipment Company 
  Autoclave Hirayama,Hiclave HV-110,Japan 
Balance Sartorius, BP221S, Germany 
 
Schimadzu, Libror EB-3200 HU, Japan 
Biomolecular Imager ImageQuant LAS 4000 mini - GE Healthcare, USA 
Cell Counter Cole Parmer, USA 
Centrifuge Eppendorf, 5415D, Germany 
 
Hitachi, Sorvall RC5C Plus, USA 
CO2 Incubator Binder,Germany 
Deepfreeze -80oC, Forma,Thermo ElectronCorp.,USA 
 
-20oC,Bosch,Turkey 
Distilled Water Millipore, Elix-S, France 
Electrophoresis Apparatus Biogen Inc., USA 
 
Biorad Inc., USA 
Electroporator Neon Transfection System - Life Technologies, USA 
Filter Membranes Millipore,USA 
Flow Cytometer BDFACSCanto,USA 
Gel Documentation Biorad, UV-Transilluminator 2000, USA 
Heater ThermomixerComfort,Eppendorf,Germany 
Hematocytometer Hausser Scientific,Blue Bell Pa.,USA 
Ice Machine Scotsman Inc., AF20, USA 
Incubator Memmert, Modell 300, Germany 
 
Memmert, Modell 600, Germany 
Laminar Flow Kendro Lab.  Prod., Heraeus, HeraSafe HS12, Germany 
Liquid Nitrogen Tank Taylor-Wharton,3000RS,USA 
Magnetic Stirrer VELP Scientifica, ARE Heating Magnetic Stirrer, Italy 
Microliter Pipettes Gilson, Pipetman, France 
 
Eppendorf, Germany 
Microscope Olympus CK40,Japan 
 
Olympus CH20,Japan 
 
Olympus IX70,Japan 
 
 Zeiss Confocal LSM710, German 
Microwave Oven Bosch,Turkey 
pH meter WTW, pH540 GLP MultiCal, Germany 
Power Supply Biorad, PowerPac 300, USA 
Refrigerator Bosch,Turkey 
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Shaker Incubator New Brunswick Sci., Innova 4330, USA 
Spectrophotometer Schimadzu, UV-1208, Japan 
 
Schimadzu, UV-3150, Japan 
Thermocycler Eppendorf, Mastercycler Gradient, Germany 
Vortex Velp Scientifica,Italy 
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APPENDIX C: DNA and Protein Molecular Weight Markers 
 
 
 
 
Figure C.1: DNA and Protein Molecular Weight Markers 
 
 
